<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN" "JATS-archivearticle1.dtd"> 
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="review-article"><?properties open_access?><?DTDIdentifier.IdentifierValue -//NLM//DTD Journal Archiving and Interchange DTD v3.0 20080202//EN?><?DTDIdentifier.IdentifierType public?><?SourceDTD.DTDName archivearticle3.dtd?><?SourceDTD.Version 3.0?><?ConverterInfo.XSLTName jp2nlmx2.xsl?><?ConverterInfo.Version 1?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Int AIDS Soc</journal-id><journal-id journal-id-type="iso-abbrev">J Int AIDS Soc</journal-id><journal-id journal-id-type="doi">10.1002/(ISSN)1758-2652</journal-id><journal-id journal-id-type="publisher-id">JIA2</journal-id><journal-title-group><journal-title>Journal of the International AIDS Society</journal-title></journal-title-group><issn pub-type="epub">1758-2652</issn><publisher><publisher-name>John Wiley and Sons Inc.</publisher-name><publisher-loc>Hoboken</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmcid">5810329</article-id><article-id pub-id-type="doi">10.1002/jia2.25066</article-id><article-id pub-id-type="publisher-id">JIA225066</article-id><article-categories><subj-group subj-group-type="overline"><subject>Review</subject></subj-group><subj-group subj-group-type="heading"><subject>Reviews</subject></subj-group></article-categories><title-group><article-title>Adherence to antiretroviral therapy for <styled-content style="fixed-case">HIV</styled-content>/<styled-content style="fixed-case">AIDS</styled-content> in Latin America and the Caribbean: Systematic review and meta&#x02010;analysis</article-title><alt-title alt-title-type="left-running-head">Costa JDM et&#x000a0;al.</alt-title></title-group><contrib-group><contrib id="jia225066-cr-0001" contrib-type="author"><name><surname>Costa</surname><given-names>Jessica de Mattos</given-names></name><xref ref-type="aff" rid="jia225066-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jia225066-cr-0002" contrib-type="author" corresp="yes"><name><surname>Torres</surname><given-names>Thiago Silva</given-names></name><contrib-id contrib-id-type="orcid">http://orcid.org/0000-0002-2557-601X</contrib-id><address><email>thiago.torres@ini.fiocruz.br</email></address><xref ref-type="aff" rid="jia225066-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jia225066-cr-0003" contrib-type="author"><name><surname>Coelho</surname><given-names>Lara Esteves</given-names></name><xref ref-type="aff" rid="jia225066-aff-0001">
<sup>1</sup>
</xref></contrib><contrib id="jia225066-cr-0004" contrib-type="author"><name><surname>Luz</surname><given-names>Paula Mendes</given-names></name><xref ref-type="aff" rid="jia225066-aff-0001">
<sup>1</sup>
</xref></contrib></contrib-group><aff id="jia225066-aff-0001">
<label><sup>1</sup></label>
<named-content content-type="organisation-division">Instituto Nacional de Infectologia Evandro Chagas</named-content>
<institution>Funda&#x000e7;&#x000e3;o Oswaldo Cruz</institution>
<named-content content-type="city">Rio de Janeiro</named-content>
<country country="BR">Brazil</country>
</aff><author-notes><corresp id="correspondenceTo"><label>*</label><bold>Corresponding author:</bold> Thiago Silva Torres, Instituto Nacional de Infectologia Evandro Chagas, Funda&#x000e7;&#x000e3;o Oswaldo Cruz, Av. Brasil 4365, 21045&#x02010;900 Rio de Janeiro, Brazil. Tel: +5521&#x000a0;3865&#x000a0;9573. (<email>thiago.torres@ini.fiocruz.br</email>)</corresp></author-notes><pub-date pub-type="epub"><day>22</day><month>1</month><year>2018</year></pub-date><pub-date pub-type="collection"><month>1</month><year>2018</year></pub-date><volume>21</volume><issue>1</issue><issue-id pub-id-type="doi">10.1002/jia2.2018.21.issue-1</issue-id><elocation-id>e25066</elocation-id><history><date date-type="received"><day>18</day><month>8</month><year>2017</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2017</year></date></history><permissions><!--<copyright-statement content-type="issue-copyright"> &#x000a9; 2018 International AIDS Society <copyright-statement>--><copyright-statement content-type="article-copyright">&#x000a9; 2018 The Authors. Journal of the International AIDS Society published by John Wiley &#x00026; sons Ltd on behalf of the International AIDS Society.</copyright-statement><license license-type="creativeCommonsBy"><license-p>This is an open access article under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution</ext-link> License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri content-type="pdf" xlink:type="simple" xlink:href="file:JIA2-21-e25066.pdf"/><abstract id="jia225066-abs-0001"><title>Abstract</title><sec id="jia225066-sec-0001"><title>Introduction</title><p>Optimal adherence to antiretroviral therapy is closely related with suppression of the <styled-content style="fixed-case">HIV</styled-content> viral load in plasma, slowing disease progression and decreasing <styled-content style="fixed-case">HIV</styled-content> transmission rates. Despite its importance, the estimated proportion of people living with <styled-content style="fixed-case">HIV</styled-content> in Latin America and the Caribbean with optimal adherence has not yet been reported in a meta&#x02010;analysis. Moreover, little is known of the factors leading to poor adherence which may be setting&#x02010;specific. We present a pooled estimate of adherence to antiretroviral therapy (<styled-content style="fixed-case">ART</styled-content>) of people living with <styled-content style="fixed-case">HIV</styled-content> in Latin America and Caribbean, report the methods used to measure adherence and describe the factors associated with poor adherence among the selected studies.</p></sec><sec id="jia225066-sec-0002"><title>Methods</title><p>We electronically searched published studies up to July 2016 on the PubMed, Web of Science and Virtual Health Library (Latin America and the Caribbean Regional Portal); considering the following databases: <styled-content style="fixed-case">MEDLINE</styled-content>,<styled-content style="fixed-case"> LILACS</styled-content>,<styled-content style="fixed-case"> PAHO</styled-content> and <styled-content style="fixed-case">IBECS</styled-content>. Two independent reviewers selected and extracted data on <styled-content style="fixed-case">ART</styled-content> adherence and study characteristics. Pooled estimate of adherence was derived using a random&#x02010;effects model. Risk of bias in individual studies was assessed independently by two investigators using the Risk of Bias Assessment tool for Non&#x02010;randomized Studies (Ro<styled-content style="fixed-case">BANS</styled-content>).</p></sec><sec id="jia225066-sec-0003"><title>Results and discussion</title><p>The meta&#x02010;analysis included 53 studies published between 2005 and 2016, which analysed 22,603 people living with <styled-content style="fixed-case">HIV</styled-content> in 25 Latin America and Caribbean countries. Overall adherence in Latin America and Caribbean was 70% (95% <styled-content style="fixed-case">CI</styled-content>: 63&#x02013;76; <italic>I</italic>
<sup><italic>2</italic></sup>&#x000a0;=&#x000a0;98%), similar to levels identified by studies conducted in high&#x02010;income regions. Self&#x02010;report was the most frequently used method to measure adherence. Subgroup analysis showed that adherence was higher for the shortest recall time frame used, as well as in countries with lower income level, Gross National Income (<styled-content style="fixed-case">GNI</styled-content>) per capita and Human Development Index (<styled-content style="fixed-case">HDI</styled-content>). Studies reported diverse adherence barriers, such as alcohol and substance misuse, depression, unemployment and pill burden.</p></sec><sec id="jia225066-sec-0004"><title>Conclusions</title><p>Our study suggests that adherence to <styled-content style="fixed-case">ART</styled-content> in Latin America and Caribbean may be below the sufficient levels required for a successful long&#x02010;term viral load suppression.</p></sec></abstract><kwd-group kwd-group-type="author-generated"><kwd id="jia225066-kwd-0001">anti&#x02010;<styled-content style="fixed-case">HIV</styled-content> agents</kwd><kwd id="jia225066-kwd-0002">antiretroviral therapy</kwd><kwd id="jia225066-kwd-0003">Caribbean region</kwd><kwd id="jia225066-kwd-0004">developing countries</kwd><kwd id="jia225066-kwd-0005">highly active</kwd><kwd id="jia225066-kwd-0006">Latin America</kwd><kwd id="jia225066-kwd-0007">medication adherence</kwd></kwd-group><funding-group><award-group><funding-source>CAPES</funding-source></award-group><award-group><funding-source>FAPERJ</funding-source></award-group><award-group><funding-source>Instituto Nacional de Infectologia Evandro Chagas &#x02010; Fiocruz</funding-source></award-group><award-group><funding-source>National Council of Technological and Scientific Development</funding-source></award-group></funding-group><counts><fig-count count="5"/><table-count count="3"/><page-count count="20"/><word-count count="14027"/></counts><custom-meta-group><custom-meta><meta-name>source-schema-version-number</meta-name><meta-value>2.0</meta-value></custom-meta><custom-meta><meta-name>component-id</meta-name><meta-value>jia225066</meta-value></custom-meta><custom-meta><meta-name>cover-date</meta-name><meta-value>January 2018</meta-value></custom-meta><custom-meta><meta-name>details-of-publishers-convertor</meta-name><meta-value>Converter:WILEY_ML3GV2_TO_NLMPMC version:version=5.3.2.2 mode:remove_FC converted:13.02.2018</meta-value></custom-meta></custom-meta-group></article-meta><notes><p content-type="self-citation">
<mixed-citation publication-type="journal" id="jia225066-cit-1001">
<string-name>
<surname>Costa</surname>, <given-names>J. M.</given-names>
</string-name>, <string-name>
<surname>Torres</surname>, <given-names>T. S.</given-names>
</string-name>, <string-name>
<surname>Coelho</surname>, <given-names>L. E.</given-names>
</string-name>, <string-name>
<surname>Luz</surname>, <given-names>P. M.</given-names>
</string-name>
<article-title>Adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean: Systematic review and meta&#x02010;analysis</article-title>. <source>J Int AIDS Soc</source>. <year>2018</year>; <volume>21</volume>(<issue>1</issue>):<elocation-id>e25066</elocation-id>
</mixed-citation>
</p></notes></front><body><def-list list-content="abbreviations" id="jia225066-dl-0001"><title>Abbreviations</title><def-item><term>ACTG</term><def><p>AIDS Clinical Trials Group</p></def></def-item><def-item><term>ART</term><def><p>antiretroviral therapy</p></def></def-item><def-item><term>CAT&#x02010;VIH</term><def><p>
<italic>Cuestionario de Adherencia al Tratamiento para el VIH/SIDA</italic>
</p></def></def-item><def-item><term>CEAT&#x02010;VIH</term><def><p>
<italic>Cuestionario para la Evaluaci&#x000f3;n de la Adhesi&#x000f3;n al Tratamiento antirretroviral</italic>
</p></def></def-item><def-item><term>GNI</term><def><p>gross national income</p></def></def-item><def-item><term>HDI</term><def><p>human development index</p></def></def-item><def-item><term>LAC</term><def><p>Latin America and the Caribbean</p></def></def-item><def-item><term>PLHIV</term><def><p>people living with HIV</p></def></def-item><def-item><term>PMAQ</term><def><p>Patient Medication Adherence Questionnaire</p></def></def-item><def-item><term>PRISMA</term><def><p>preferred reporting items for systematic reviews and meta&#x02010;Analyses</p></def></def-item><def-item><term>RCT</term><def><p>randomized controlled trial</p></def></def-item><def-item><term>RoBANS</term><def><p>risk of bias assessment tool for non&#x02010;randomized studies</p></def></def-item><def-item><term>SMAQ</term><def><p>Simplified Medication Adherence Questionnaire</p></def></def-item><def-item><term>VAS</term><def><p>visual analogue scale</p></def></def-item><def-item><term>VPAD&#x02010;24</term><def><p>
<italic>Variables psicol&#x000f3;gicas y comportamientos de adhesi&#x000f3;n</italic>
</p></def></def-item></def-list><sec id="jia225066-sec-0005"><label>1</label><title>Introduction</title><p>Latin America and the Caribbean (LAC) consists of 33 sovereign countries which cover an area that stretches from the northern border of Mexico to the southern tip of Chile, including the Caribbean. It has an area of over 20 million km<sup>2</sup>, as of 2017, its population was estimated at approximately 650 million (~9% of the world population), being predominantly urban (80%) <xref rid="jia225066-bib-0001" ref-type="ref">1</xref>. LAC is mostly a developing region which had a combined nominal gross domestic product (GDP) of 5,5 trillion USD and a GDP purchasing power parity (PPP) of 9.7 trillion USD in 2017 <xref rid="jia225066-bib-0002" ref-type="ref">2</xref>. By 2015, the region's HDI was 0.731 (high), varying from 0.493 (Haiti, low) to 0.847 (Chile, very high) <xref rid="jia225066-bib-0003" ref-type="ref">3</xref>.</p><p>Antiretroviral therapy (ART) revolutionized the treatment of people living with HIV (PLHIV) by dramatically decreasing their morbidity and mortality <xref rid="jia225066-bib-0004" ref-type="ref">4</xref>. In LAC region there were 2.1 million PLHIV and more than 1.1 million PLHIV on ART by the end of 2016 <xref rid="jia225066-bib-0005" ref-type="ref">5</xref>. Indeed, studies have indicated promising results in the region with regards to the HIV Care Continuum: clinical retention, ART use and viral suppression significantly improved from 2003 to 2012 (63 to 77%, 74 to 91% and 53 to 82% respectively; <italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05, each), though disparities for vulnerable groups, such as female sex workers, people who inject drugs, gay men and other men who have sex with men, remain <xref rid="jia225066-bib-0006" ref-type="ref">6</xref>.</p><p>Argentina, Bolivia, Brazil, Costa Rica, Mexico, Paraguay, Uruguay and Venezuela, in Latin America; and Antigua and Barbuda, Bahamas, Barbados, Saint Vincent and the Grenadines, and Trinidad and Tobago, in the Caribbean, have now adopted the World Health Organization recommendation of initiation of ART for all PLHIV irrespective of CD4 cell count <xref rid="jia225066-bib-0007" ref-type="ref">7</xref>. ART coverage reaches 58% (95% confidence interval [95%CI] 42&#x02013;72%) and 52% (95%CI 41&#x02013;60%) of all PLHIV in LAC, respectively <xref rid="jia225066-bib-0007" ref-type="ref">7</xref>. At the country level, treatment coverage was 70% in Cuba, followed by 64% in Argentina, 62% in Trinidad and Tobago and 60% in Brazil and Mexico. On the other hand, Bolivia had only 25%, Paraguay had 35% and Guatemala had 36% of PLHIV accessing treatment in 2016 <xref rid="jia225066-bib-0005" ref-type="ref">5</xref>. From 2010 to 2016, the number of deaths has not dramatically decreased (12% of decrease in Latina America and 28% in the Caribbean) and, most significantly, the number of new infections remained relatively stable (0% of decrease in Latin America and 5% decrease in the Caribbean) <xref rid="jia225066-bib-0005" ref-type="ref">5</xref>. This stability hides big differences between countries. In Latin America, although new infections have decreased by more than 20% in Colombia, El Salvador, Nicaragua and Uruguay, they increased significantly in Chile (34%), followed by Guatemala (23%), Costa Rica (16%), Honduras (11%) and Panama (9%); and slightly in Argentina and Brazil (3%). In the Caribbean, the majority of new infections occurred in Cuba, where estimated numbers of new HIV infections more than doubled between 2010 and 2016 <xref rid="jia225066-bib-0007" ref-type="ref">7</xref>, despite of the dramatic increase in treatment coverage <xref rid="jia225066-bib-0005" ref-type="ref">5</xref>.</p><p>The Political Declaration on Ending AIDS by 2030 <xref rid="jia225066-bib-0008" ref-type="ref">8</xref> established specific goals for LAC region, which included reducing the number of new infections in LAC from 100,000 to 40,000 and increasing the number of PLHIV on ART from 1.1 to 1.6 million by 2020. Achievement of these goals will be challenging, requiring continued efforts from governments and international agencies.</p><p>Specifically, the HIV epidemic cannot be ended without containing the new infections, and adherence to ART plays an important role in this process. ART adherence is closely linked to suppression of the HIV viral load in plasma <xref rid="jia225066-bib-0009" ref-type="ref">9</xref>, <xref rid="jia225066-bib-0010" ref-type="ref">10</xref> which leads to immune reconstitution and also decreases onward HIV transmission <xref rid="jia225066-bib-0011" ref-type="ref">11</xref>. The optimal adherence level to achieve viral suppression is unclear, though the 95% threshold established by Paterson et&#x000a0;al. has largely been used as a goal <xref rid="jia225066-bib-0009" ref-type="ref">9</xref>. More recently, other authors demonstrated that high levels of viral suppression could be obtained with adherence levels below 95% when in use of newer ART regimens <xref rid="jia225066-bib-0012" ref-type="ref">12</xref>, <xref rid="jia225066-bib-0013" ref-type="ref">13</xref>, <xref rid="jia225066-bib-0014" ref-type="ref">14</xref>, <xref rid="jia225066-bib-0015" ref-type="ref">15</xref>, <xref rid="jia225066-bib-0016" ref-type="ref">16</xref>. The monitoring of ART adherence is highly recommended by health organizations <xref rid="jia225066-bib-0017" ref-type="ref">17</xref> and the main methods are: self&#x02010;report by interview, pill counts, pharmacy refill and medication event monitoring system (MEMS). Monitoring patient's ART adherence is a challenging but critical way to identify those with poor adherence.</p><p>Even though there is a huge difference in socio&#x02010;cultural characteristics across countries in LAC, there are still similar inequalities and traditional values that may act as barriers for HIV treatment, which may impact adherence to ART. This is more pronounced among high&#x02010;risk populations, who are more vulnerable to social inequalities, discrimination and violence. However, little is known of the factors leading to poor adherence which may be setting&#x02010;specific. Although ART coverage has increased in the region, the fact that the number of new infections remained relatively stable may be related to the lack of adherence to ART.</p><p>In this meta&#x02010;analysis, we synthesize the published peer reviewed literature, generating a pooled estimate of adherence to ART of PLHIV in LAC. In addition, we present the adherence proportion according to the country's income level, Human Development Index (HDI) rank, and Gross National Income (GNI) per capita, as well as other factors as detailed in the Methods section. We qualitatively synthetize the methods used to monitor adherence and describe the factors associated with poor adherence among the selected studies. Greater knowledge of ART adherence levels of PLHIV in LAC may provide means to improve patient care and could help Governments and regional institutions to accomplish the goal of ending AIDS by 2030.</p></sec><sec id="jia225066-sec-0006"><label>2</label><title>Methods</title><p>This systematic review and meta&#x02010;analysis has been reported according to the <italic>Preferred reporting items for systematic reviews and meta&#x02010;Analyses</italic> (PRISMA) <italic>Statement</italic>
<xref rid="jia225066-bib-0018" ref-type="ref">18</xref>.</p><sec id="jia225066-sec-0007"><label>2.1</label><title>Protocol and registration</title><p>Key information about the design and conduct of this systematic review and meta&#x02010;analysis are recorded at the international database of prospectively registered systematic reviews in health and social care (PROSPERO 2017:CRD42017055963) <xref rid="jia225066-bib-0019" ref-type="ref">19</xref>.</p></sec><sec id="jia225066-sec-0008"><label>2.2</label><title>Eligibility criteria</title><p>Studies of any design were included if they met&#x000a0;all the following criteria: (i) the study involved people living with HIV/AIDS in Latin America and the Caribbean (studies involving participants from other regions were included if we could clearly identify data from LAC participants); (ii) participants were receiving antiretroviral therapy; (iii) and treatment adherence was quantified. Studies were excluded if they included pregnant women and did not stratified adherence for the non&#x02010;pregnant participants, because of specific features of their ART (treatment aimed at preventing vertical transmission of HIV and not as treatment of infection). Also, studies were excluded if they assessed alternative forms of treatment (for example, due to some specific co&#x02010;infection), or if antiretrovirals were being used for post or pre&#x02010;exposure prophylaxis. Similarly, we excluded studies focusing only on participants less than 18&#x000a0;years of age or specific populations (for example, only individuals previously found to have low adherence, or homeless populations). Studies including both adults and participants less than 18&#x000a0;years of age were not excluded if adherence data was stratified by age (and in this case, data from the age categories &#x0003c;18&#x000a0;years were not considered in the present analysis). Articles published before 2005 were excluded to avoid studies in the pre&#x02010;HAART era. Also, grey literature was not considered in this study (such as thesis, dissertations, monographies, conference papers and reports).</p></sec><sec id="jia225066-sec-0009"><label>2.3</label><title>Information sources and search strategy</title><p>Articles were identified through searches conducted on 14 July 2016 on PubMed, Web of Science and Virtual Health Library (Latin America and the Caribbean Regional Portal) considering the following databases: MEDLINE, LILACS, PAHO and IBECS. The search combined terms derived from four domains: (a) adherence; (b) HIV; (c) antiretroviral (d) countries of Latin America and the Caribbean (see Additional file <xref rid="jia225066-sup-0001" ref-type="supplementary-material">1</xref> for the full PubMed search strategy). Citations were inserted into the study database when the four domains were jointly present in the title, abstract, MeSH terms or keywords. No limits were applied for language or publication date in the search. A reference manager (Zotero) was used to collect and organize search results and for duplicate removal.</p></sec><sec id="jia225066-sec-0010"><label>2.4</label><title>Study selection</title><p>Two investigators (JMC, TST) reviewed all abstracts and full&#x02010;text articles independently, according to the eligibility criteria. Discrepancies were adjudicated by an independent third investigator (PML).</p></sec><sec id="jia225066-sec-0011"><label>2.5</label><title>Data collection process</title><p>Data extraction was performed independently by two investigators (JMC, TST) using a predefined extraction form. Each paper was coded for publication characteristics (authors, publication year, full title, journal and language), study characteristics (years when data was collected, country(ies) where the study was performed, study design, sample size, recruitment setting and number of study centres), participants characteristics (age, sex and race/ethnicity), adherence monitoring characteristics (method for adherence measurement, cutoff of optimal adherence, proportion of adherents, time frame used to measure adherence), and the factors significantly associated with adherence (<italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05) on multivariate modelling. Discrepancies in extracted data were adjudicated by an independent third investigator (PML).</p></sec><sec id="jia225066-sec-0012"><label>2.6</label><title>Study definitions</title><p>Adherence was estimated for each study by dividing the number of individuals with optimal adherence by the number of individuals evaluated. This implies that our overall pooled adherence was based on the adherence threshold adopted in each study. When a study examined the effect of an intervention on ART adherence, only the adherence result at baseline was considered. In case there was no baseline assessment, only the first adherence assessment of the control group was extracted and analysed. As adopted in prior studies <xref rid="jia225066-bib-0020" ref-type="ref">20</xref>, <xref rid="jia225066-bib-0021" ref-type="ref">21</xref> when more than one adherence measurement was reported, the most objective method was chosen for the analysis (e.g. medication event monitoring system (MEMS)&#x000a0;&#x0003e;&#x000a0;pill count&#x000a0;&#x0003e;&#x000a0;pharmacy refill&#x000a0;&#x0003e;&#x000a0;self&#x02010;reported adherence in the past week&#x000a0;&#x0003e;&#x000a0;self&#x02010;reported adherence in the past month). When an optimal adherence threshold (e.g. &#x02265;80 or &#x02265;95%) was not explicitly defined in the study and adherence was categorized in levels (for example, low, regular and strict; or 65<bold>&#x02013;</bold>84%, 85<bold>&#x02013;</bold>94% and 95<bold>&#x02013;</bold>100%), the highest adherence category was considered.</p><p>For subgroup analysis, adherence recall time frame was categorized in four periods: 3&#x02013;4 days, 7 days, 30&#x000a0;days and 90&#x000a0;days. Location/country was classified by geographical area and categorized as: Brazil, South America (Chile, Colombia, Peru), Central America and Caribbean (Cuba, Dominican Republic, Guatemala, Haiti, Jamaica), North America (Puerto Rico and Mexico) and multi&#x02010;region (included countries from more than one region). Time period when study was conducted was categorized as &#x02264;2005, 2006<bold>&#x02013;</bold>2010 and &#x02265;2011. Study design was categorized as cross&#x02010;sectional, longitudinal (non&#x02010;RCT) and RCT. Income group was categorized by low/lower middle, upper middle, high and mix, following the World Bank definitions for 2017 <xref rid="jia225066-bib-0022" ref-type="ref">22</xref>. HDI and GNI per capita data were extracted from the Human Development Reports of the United Nations Development Programme <xref rid="jia225066-bib-0003" ref-type="ref">3</xref>. The HDI is a composite index measuring average achievement in three basic dimensions of human development &#x02010; a long and healthy life, knowledge and a decent standard of living <xref rid="jia225066-bib-0003" ref-type="ref">3</xref>; while the GNI per capita reflects the average income of a country's citizens <xref rid="jia225066-bib-0003" ref-type="ref">3</xref>. HDI ranking and the GNI per capita, were classified in two categories each (HDI: &#x0003c;0.754 and &#x02265;0.754; GNI per capita in USD: &#x0003c;14,145 and &#x02265;14,145). When a study involved multiple countries, the lower HDI or GNI value was considered, though we repeated the analysis considering the highest HDI and GNI values and the results changed minimally. Number of study sites was categorized as single&#x02010;site, multi&#x02010;site and online (participants accessed and completed survey via an online portal). Treatment experience was categorized as na&#x000ef;ve (included individuals who had just recently started ART, usually within six months), experienced (included individuals who had been using ART for some time) and na&#x000ef;ve and experienced. Instrument used to measure adherence were categorized as self&#x02010;report, MEMS, self&#x02010;report+drug refill and self&#x02010;report+pill count. Adherence threshold was categorized as &#x0003c;94% (when threshold was &#x02265;64%, &#x02265;80%, &#x02265;85% or &#x02265;90%), 95% (when threshold was &#x02265;95%), 100% and not reported. Finally, the presence of statistical models evaluating factors associated with adherence (YES/NO) was evaluated in subgroup analysis.</p></sec><sec id="jia225066-sec-0013"><label>2.7</label><title>Risk of bias in individual studies</title><p>The quality of the included studies was assessed by two investigators (PML, LEC) using the Risk of Bias Assessment tool for Non&#x02010;randomized Studies (RoBANS) <xref rid="jia225066-bib-0023" ref-type="ref">23</xref>. RoBANS includes criteria for judging the risk of bias for each domain. The risk of bias in a study was graded as low, high or unclear based on the following study features: selection of participants (selection bias), consideration of confounding variables (selection bias), measurement of exposure (detection bias), handling of incomplete outcome data (attrition bias) and selective outcome reporting (reporting bias).</p></sec><sec id="jia225066-sec-0014"><label>2.8</label><title>Data synthesis</title><p>Logit transformation of the proportions and their standard errors were calculated to achieve a normal distribution which is required for the pooling of data <xref rid="jia225066-bib-0024" ref-type="ref">24</xref>. Pooled adherence proportion was calculated using the DerSimonian&#x02010;Laird method <xref rid="jia225066-bib-0025" ref-type="ref">25</xref> assuming a random&#x02010;effects model. Heterogeneity between studies was initially evaluated by visual inspection of forest&#x02010;plots. The proportion of true heterogeneity to total variance was calculated by the Higgins <italic>I</italic>
<sup>2</sup> statistic <xref rid="jia225066-bib-0026" ref-type="ref">26</xref>.</p></sec><sec id="jia225066-sec-0015"><label>2.9</label><title>Additional analyses</title><p>We conducted subgroup analyses and estimated the pooled adherence proportion according to adherence recall time frame, location/country, time period when study was conducted, study design, country's income level, HDI rank, GNI per capita, sites, treatment experience, instrument to measure adherence, adherence threshold, and presence of statistical models evaluating factors associated with adherence.</p></sec></sec><sec id="jia225066-sec-0016"><label>3</label><title>Results</title><sec id="jia225066-sec-0017"><label>3.1</label><title>Study Characteristics</title><p>The flow diagram of study selection is shown in Figure&#x000a0;<xref rid="jia225066-fig-0001" ref-type="fig">1</xref>. Fifty&#x02010;three studies, composed of 22,603 participants in ART from 25 LAC countries, met eligibility criteria for the systematic review (Table&#x000a0;<xref rid="jia225066-tbl-0001" ref-type="table-wrap">1</xref>) <xref rid="jia225066-bib-0027" ref-type="ref">27</xref>, <xref rid="jia225066-bib-0028" ref-type="ref">28</xref>, <xref rid="jia225066-bib-0029" ref-type="ref">29</xref>, <xref rid="jia225066-bib-0030" ref-type="ref">30</xref>, <xref rid="jia225066-bib-0031" ref-type="ref">31</xref>, <xref rid="jia225066-bib-0032" ref-type="ref">32</xref>, <xref rid="jia225066-bib-0033" ref-type="ref">33</xref>, <xref rid="jia225066-bib-0034" ref-type="ref">34</xref>, <xref rid="jia225066-bib-0035" ref-type="ref">35</xref>, <xref rid="jia225066-bib-0036" ref-type="ref">36</xref>, <xref rid="jia225066-bib-0037" ref-type="ref">37</xref>, <xref rid="jia225066-bib-0038" ref-type="ref">38</xref>, <xref rid="jia225066-bib-0039" ref-type="ref">39</xref>, <xref rid="jia225066-bib-0040" ref-type="ref">40</xref>, <xref rid="jia225066-bib-0041" ref-type="ref">41</xref>, <xref rid="jia225066-bib-0042" ref-type="ref">42</xref>, <xref rid="jia225066-bib-0043" ref-type="ref">43</xref>, <xref rid="jia225066-bib-0044" ref-type="ref">44</xref>, <xref rid="jia225066-bib-0045" ref-type="ref">45</xref>, <xref rid="jia225066-bib-0046" ref-type="ref">46</xref>, <xref rid="jia225066-bib-0047" ref-type="ref">47</xref>, <xref rid="jia225066-bib-0048" ref-type="ref">48</xref>, <xref rid="jia225066-bib-0049" ref-type="ref">49</xref>, <xref rid="jia225066-bib-0050" ref-type="ref">50</xref>, <xref rid="jia225066-bib-0051" ref-type="ref">51</xref>, <xref rid="jia225066-bib-0052" ref-type="ref">52</xref>, <xref rid="jia225066-bib-0053" ref-type="ref">53</xref>, <xref rid="jia225066-bib-0054" ref-type="ref">54</xref>, <xref rid="jia225066-bib-0055" ref-type="ref">55</xref>, <xref rid="jia225066-bib-0056" ref-type="ref">56</xref>, <xref rid="jia225066-bib-0057" ref-type="ref">57</xref>, <xref rid="jia225066-bib-0058" ref-type="ref">58</xref>, <xref rid="jia225066-bib-0059" ref-type="ref">59</xref>, <xref rid="jia225066-bib-0060" ref-type="ref">60</xref>, <xref rid="jia225066-bib-0061" ref-type="ref">61</xref>, <xref rid="jia225066-bib-0062" ref-type="ref">62</xref>, <xref rid="jia225066-bib-0063" ref-type="ref">63</xref>, <xref rid="jia225066-bib-0064" ref-type="ref">64</xref>, <xref rid="jia225066-bib-0065" ref-type="ref">65</xref>, <xref rid="jia225066-bib-0066" ref-type="ref">66</xref>, <xref rid="jia225066-bib-0067" ref-type="ref">67</xref>, <xref rid="jia225066-bib-0068" ref-type="ref">68</xref>, <xref rid="jia225066-bib-0069" ref-type="ref">69</xref>, <xref rid="jia225066-bib-0070" ref-type="ref">70</xref>, <xref rid="jia225066-bib-0071" ref-type="ref">71</xref>, <xref rid="jia225066-bib-0072" ref-type="ref">72</xref>, <xref rid="jia225066-bib-0073" ref-type="ref">73</xref>, <xref rid="jia225066-bib-0074" ref-type="ref">74</xref>, <xref rid="jia225066-bib-0075" ref-type="ref">75</xref>, <xref rid="jia225066-bib-0076" ref-type="ref">76</xref>, <xref rid="jia225066-bib-0077" ref-type="ref">77</xref>, <xref rid="jia225066-bib-0078" ref-type="ref">78</xref>, <xref rid="jia225066-bib-0079" ref-type="ref">79</xref>. The median number of participants in ART per study was 201 [range: 13<bold>&#x02013;</bold>3343; interquartile range (IQR): 394<bold>&#x02013;</bold>125]. The studies were conducted between 2000 and 2013 and published from 2005 to 2016 in three different languages (English: 39; Spanish: 9; Portuguese: 5). Studies were mostly conducted in countries with an upper middle income level (81.1%).</p><fig fig-type="Figure" xml:lang="en" id="jia225066-fig-0001" orientation="portrait" position="float"><label>Figure 1</label><caption><p>Flow diagram of study selection for the meta&#x02010;analysis of adherence to antiretroviral therapy for <styled-content style="fixed-case">HIV</styled-content>/<styled-content style="fixed-case">AIDS</styled-content> in Latin America and the Caribbean, 2005&#x02013;2016. <styled-content style="fixed-case">LAC</styled-content>, Latin America and the Caribbean; <styled-content style="fixed-case">PLHIV</styled-content>&#x000a0;=&#x000a0;people living with <styled-content style="fixed-case">HIV</styled-content>.</p></caption><graphic id="nlm-graphic-1" xlink:href="JIA2-21-e25066-g001"/></fig><table-wrap id="jia225066-tbl-0001" xml:lang="en" orientation="portrait" position="float"><label>Table 1</label><caption><p>Characteristics of studies included in the meta&#x02010;analysis of adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean, 2005&#x02013;2016</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Source</th><th align="left" valign="top" rowspan="1" colspan="1">LAC country</th><th align="left" valign="top" rowspan="1" colspan="1">Study design</th><th align="char" valign="top" rowspan="1" colspan="1">N in analysis</th><th align="left" valign="top" rowspan="1" colspan="1">Adherence measure (instrument)</th><th align="left" valign="top" rowspan="1" colspan="1">Optimal adherence threshold (%)</th><th align="left" valign="top" rowspan="1" colspan="1">Recall time frame (days)</th><th align="left" valign="top" rowspan="1" colspan="1">Country's income group<xref ref-type="fn" rid="jia225066-note-0002">a</xref>
</th><th align="char" valign="top" rowspan="1" colspan="1">HDI<xref ref-type="fn" rid="jia225066-note-0003">b</xref>
</th><th align="left" valign="top" rowspan="1" colspan="1">GNI per capita<xref ref-type="fn" rid="jia225066-note-0003">b</xref>
</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Alave et&#x000a0;al., 2013 <xref rid="jia225066-bib-0048" ref-type="ref">48</xref>
</td><td align="left" rowspan="1" colspan="1">Peru</td><td align="left" rowspan="1" colspan="1">Non&#x02010;RCT longitudinal</td><td align="char" char="." rowspan="1" colspan="1">1478</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x0003e;95</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">11,295</td></tr><tr><td align="left" rowspan="1" colspan="1">Allen et&#x000a0;al., 2011 <xref rid="jia225066-bib-0038" ref-type="ref">38</xref>
</td><td align="left" rowspan="1" colspan="1">Antigua and Barbuda, Grenada, Trinidad and Tobago</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">274</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Upper middle and high</td><td align="char" char="." rowspan="1" colspan="1">0.754&#x02013;0.786</td><td align="left" rowspan="1" colspan="1">11,502&#x02013;28,049</td></tr><tr><td align="left" rowspan="1" colspan="1">Amico et&#x000a0;al., 2005 <xref rid="jia225066-bib-0029" ref-type="ref">29</xref>
</td><td align="left" rowspan="1" colspan="1">Puerto Rico</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">196</td><td align="left" rowspan="1" colspan="1">SR (modified ACTG)</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">High</td><td align="left" rowspan="1" colspan="1">Not available</td><td align="left" rowspan="1" colspan="1">Not available</td></tr><tr><td align="left" rowspan="1" colspan="1">Aragon&#x000e9;s et&#x000a0;al., 2011 <xref rid="jia225066-bib-0039" ref-type="ref">39</xref>
</td><td align="left" rowspan="1" colspan="1">Cuba</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">781</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.775</td><td align="left" rowspan="1" colspan="1">7455</td></tr><tr><td align="left" rowspan="1" colspan="1">Arrivillaga et&#x000a0;al., 2009 <xref rid="jia225066-bib-0036" ref-type="ref">36</xref>
</td><td align="left" rowspan="1" colspan="1">Colombia</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">269</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x02265;64</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.727</td><td align="left" rowspan="1" colspan="1">12,762</td></tr><tr><td align="left" rowspan="1" colspan="1">Balandr&#x000e1;n et&#x000a0;al., 2013 <xref rid="jia225066-bib-0056" ref-type="ref">56</xref>
</td><td align="left" rowspan="1" colspan="1">Mexico</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">2054</td><td align="left" rowspan="1" colspan="1">SR (ACTG)</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.762</td><td align="left" rowspan="1" colspan="1">16,383</td></tr><tr><td align="left" rowspan="1" colspan="1">Basso et&#x000a0;al., 2013 <xref rid="jia225066-bib-0055" ref-type="ref">55</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">RCT</td><td align="char" char="." rowspan="1" colspan="1">108</td><td align="left" rowspan="1" colspan="1">MEMS</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Biello et&#x000a0;al., 2016 <xref rid="jia225066-bib-0078" ref-type="ref">78</xref>
</td><td align="left" rowspan="1" colspan="1">17 countries<xref ref-type="fn" rid="jia225066-note-0004">c</xref>
</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">1637</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Lower middle, upper middle and high</td><td align="char" char="." rowspan="1" colspan="1">0.625&#x02013;0.847</td><td align="left" rowspan="1" colspan="1">4466 &#x02013;21,665</td></tr><tr><td align="left" rowspan="1" colspan="1">Bonolo et&#x000a0;al., 2005 <xref rid="jia225066-bib-0027" ref-type="ref">27</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Non&#x02010;RCT longitudinal</td><td align="char" char="." rowspan="1" colspan="1">306</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Calvetti et&#x000a0;al., 2014 <xref rid="jia225066-bib-0057" ref-type="ref">57</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">SR (CEAT&#x02010;VIH)</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Campbell et&#x000a0;al., 2010 <xref rid="jia225066-bib-0037" ref-type="ref">37</xref>
</td><td align="left" rowspan="1" colspan="1">Guatemala</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">122</td><td align="left" rowspan="1" colspan="1">SR (VAS)&#x000a0;&#x0003e;&#x000a0;Pill count</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Lower middle</td><td align="char" char="." rowspan="1" colspan="1">0.64</td><td align="left" rowspan="1" colspan="1">7063</td></tr><tr><td align="left" rowspan="1" colspan="1">Cardona&#x02010;Arias et&#x000a0;al., 2011 <xref rid="jia225066-bib-0040" ref-type="ref">40</xref>
</td><td align="left" rowspan="1" colspan="1">Colombia</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">146</td><td align="left" rowspan="1" colspan="1">SR (SMAQ)</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.727</td><td align="left" rowspan="1" colspan="1">12,762</td></tr><tr><td align="left" rowspan="1" colspan="1">Carrillo et&#x000a0;al., 2009 <xref rid="jia225066-bib-0035" ref-type="ref">35</xref>
</td><td align="left" rowspan="1" colspan="1">Colombia</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">103</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.727</td><td align="left" rowspan="1" colspan="1">12,762</td></tr><tr><td align="left" rowspan="1" colspan="1">Carvalho et&#x000a0;al., 2007 <xref rid="jia225066-bib-0032" ref-type="ref">32</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Non&#x02010;RCT longitudinal</td><td align="char" char="." rowspan="1" colspan="1">150</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Casotti et&#x000a0;al., 2011 <xref rid="jia225066-bib-0041" ref-type="ref">41</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">81</td><td align="left" rowspan="1" colspan="1">SR (CEAT&#x02010;VIH)</td><td align="left" rowspan="1" colspan="1">&#x02265;85</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Costa et&#x000a0;al., 2012 <xref rid="jia225066-bib-0019" ref-type="ref">19</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">RCT</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="left" rowspan="1" colspan="1">MEMS&#x000a0;&#x0003e;&#x000a0;Pill count&#x000a0;&#x0003e;&#x000a0;SR</td><td align="left" rowspan="1" colspan="1">&#x0003e;95</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">De Boni et&#x000a0;al., 2016 <xref rid="jia225066-bib-0077" ref-type="ref">77</xref>
</td><td align="left" rowspan="1" colspan="1">6 countries<xref ref-type="fn" rid="jia225066-note-0005">d</xref>
</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">3343</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Lower middle, upper middle and high</td><td align="char" char="." rowspan="1" colspan="1">0.625&#x02013;0.847</td><td align="left" rowspan="1" colspan="1">4466&#x02013;21,665</td></tr><tr><td align="left" rowspan="1" colspan="1">De La Hoz et&#x000a0;al., 2014 <xref rid="jia225066-bib-0063" ref-type="ref">63</xref>
</td><td align="left" rowspan="1" colspan="1">Colombia</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">122</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x02265;80</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.727</td><td align="left" rowspan="1" colspan="1">12,762</td></tr><tr><td align="left" rowspan="1" colspan="1">Drachler et&#x000a0;al., 2016 <xref rid="jia225066-bib-0075" ref-type="ref">75</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Non&#x02010;RCT longitudinal</td><td align="char" char="." rowspan="1" colspan="1">267</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Ferro et&#x000a0;al., 2015 <xref rid="jia225066-bib-0064" ref-type="ref">64</xref>
</td><td align="left" rowspan="1" colspan="1">Peru</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">263</td><td align="left" rowspan="1" colspan="1">SR (VAS)</td><td align="left" rowspan="1" colspan="1">&#x02265;90</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">11,295</td></tr><tr><td align="left" rowspan="1" colspan="1">Fleming et&#x000a0;al., 2016 <xref rid="jia225066-bib-0079" ref-type="ref">79</xref>
</td><td align="left" rowspan="1" colspan="1">Dominican Republic</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.722</td><td align="left" rowspan="1" colspan="1">12,756</td></tr><tr><td align="left" rowspan="1" colspan="1">Garcia et&#x000a0;al., 2006 <xref rid="jia225066-bib-0030" ref-type="ref">30</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">182</td><td align="left" rowspan="1" colspan="1">SR (modified PMAQ)</td><td align="left" rowspan="1" colspan="1">&#x0003e;95</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Gutierrez et&#x000a0;al., 2012 <xref rid="jia225066-bib-0047" ref-type="ref">47</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">284</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">3, 7</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Hanif et&#x000a0;al., 2013 <xref rid="jia225066-bib-0049" ref-type="ref">49</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">632</td><td align="left" rowspan="1" colspan="1">SR (modified ACTG)</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Harris et&#x000a0;al., 2011 <xref rid="jia225066-bib-0042" ref-type="ref">42</xref>
</td><td align="left" rowspan="1" colspan="1">Dominican Republic</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">300</td><td align="left" rowspan="1" colspan="1">SR (VAS)</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.722</td><td align="left" rowspan="1" colspan="1">12,756</td></tr><tr><td align="left" rowspan="1" colspan="1">Ilias et&#x000a0;al., 2011 <xref rid="jia225066-bib-0043" ref-type="ref">43</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">56</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x02265;80</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Ivers et&#x000a0;al., 2014 <xref rid="jia225066-bib-0058" ref-type="ref">58</xref>
</td><td align="left" rowspan="1" colspan="1">Haiti</td><td align="left" rowspan="1" colspan="1">RCT</td><td align="char" char="." rowspan="1" colspan="1">488</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Low</td><td align="char" char="." rowspan="1" colspan="1">0.493</td><td align="left" rowspan="1" colspan="1">1657</td></tr><tr><td align="left" rowspan="1" colspan="1">Jacques et&#x000a0;al., 2014 <xref rid="jia225066-bib-0059" ref-type="ref">59</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">152</td><td align="left" rowspan="1" colspan="1">SR (CEAT&#x02010;VIH)</td><td align="left" rowspan="1" colspan="1">&#x0003e;85</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Krishnan et&#x000a0;al., 2015 <xref rid="jia225066-bib-0065" ref-type="ref">65</xref>
</td><td align="left" rowspan="1" colspan="1">Peru</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">313</td><td align="left" rowspan="1" colspan="1">SR (VAS)</td><td align="left" rowspan="1" colspan="1">&#x02265;90</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">11,295</td></tr><tr><td align="left" rowspan="1" colspan="1">Magidson et&#x000a0;al., 2015 <xref rid="jia225066-bib-0066" ref-type="ref">66</xref>
</td><td align="left" rowspan="1" colspan="1">17 countries<xref ref-type="fn" rid="jia225066-note-0006">e</xref>
</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">2211</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Lower middle, upper middle and high</td><td align="char" char="." rowspan="1" colspan="1">0.625&#x02013;0.847</td><td align="left" rowspan="1" colspan="1">4466&#x02013;21,665</td></tr><tr><td align="left" rowspan="1" colspan="1">Magidson et&#x000a0;al., 2016 <xref rid="jia225066-bib-0074" ref-type="ref">74</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">182</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">90</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Malbergier et&#x000a0;al., 2015 <xref rid="jia225066-bib-0067" ref-type="ref">67</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">438</td><td align="left" rowspan="1" colspan="1">SR (SMAQ)</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Malow et&#x000a0;al., 2013 <xref rid="jia225066-bib-0050" ref-type="ref">50</xref>
</td><td align="left" rowspan="1" colspan="1">Haiti</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">194</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Low</td><td align="char" char="." rowspan="1" colspan="1">0.493</td><td align="left" rowspan="1" colspan="1">1657</td></tr><tr><td align="left" rowspan="1" colspan="1">Mascolini et&#x000a0;al., 2008 <xref rid="jia225066-bib-0033" ref-type="ref">33</xref>
</td><td align="left" rowspan="1" colspan="1">6 countries<xref ref-type="fn" rid="jia225066-note-0007">f</xref>
</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">592</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Upper middle and high</td><td align="char" char="." rowspan="1" colspan="1">0.722&#x02013;0.827</td><td align="left" rowspan="1" colspan="1">8350<bold>&#x02013;</bold>20,945</td></tr><tr><td align="left" rowspan="1" colspan="1">Mu&#x000f1;oz et&#x000a0;al., 2011 <xref rid="jia225066-bib-0044" ref-type="ref">44</xref>
</td><td align="left" rowspan="1" colspan="1">Peru</td><td align="left" rowspan="1" colspan="1">Non&#x02010;RCT longitudinal</td><td align="char" char="." rowspan="1" colspan="1">60</td><td align="left" rowspan="1" colspan="1">SR (ACTG)</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">11,295</td></tr><tr><td align="left" rowspan="1" colspan="1">Nachega et&#x000a0;al., 2012 <xref rid="jia225066-bib-0046" ref-type="ref">46</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">201</td><td align="left" rowspan="1" colspan="1">SR (ACTG)</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Pac&#x000ed;fico et&#x000a0;al., 2015 <xref rid="jia225066-bib-0073" ref-type="ref">73</xref>
</td><td align="left" rowspan="1" colspan="1">Peru</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">364</td><td align="left" rowspan="1" colspan="1">SR (SMAQ)+Withdrawal<xref ref-type="fn" rid="jia225066-note-0008">g</xref>
</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">11,295</td></tr><tr><td align="left" rowspan="1" colspan="1">Padoin et&#x000a0;al., 2013 <xref rid="jia225066-bib-0051" ref-type="ref">51</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">125</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">P&#x000e9;rez&#x02010;Salgado et&#x000a0;al., 2015 <xref rid="jia225066-bib-0068" ref-type="ref">68</xref>
</td><td align="left" rowspan="1" colspan="1">Mexico</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">557</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x0003e;95</td><td align="left" rowspan="1" colspan="1">7,30</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.762</td><td align="left" rowspan="1" colspan="1">16,383</td></tr><tr><td align="left" rowspan="1" colspan="1">Pi&#x000f1;a L&#x000f3;pez et&#x000a0;al., 2008 <xref rid="jia225066-bib-0034" ref-type="ref">34</xref>
</td><td align="left" rowspan="1" colspan="1">Mexico</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">64</td><td align="left" rowspan="1" colspan="1">SR (VPAD&#x02010;24)</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.762</td><td align="left" rowspan="1" colspan="1">16,383</td></tr><tr><td align="left" rowspan="1" colspan="1">Remien et&#x000a0;al., 2007 <xref rid="jia225066-bib-0031" ref-type="ref">31</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">200</td><td align="left" rowspan="1" colspan="1">SR (modified ACTG)</td><td align="left" rowspan="1" colspan="1">&#x02265;90</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Santill&#x000e1;n Torres Torija et&#x000a0;al., 2015 <xref rid="jia225066-bib-0069" ref-type="ref">69</xref>
</td><td align="left" rowspan="1" colspan="1">Mexico</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">109</td><td align="left" rowspan="1" colspan="1">SR (modified ACTG)</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">30</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.762</td><td align="left" rowspan="1" colspan="1">16,383</td></tr><tr><td align="left" rowspan="1" colspan="1">Santos et&#x000a0;al., 2005 <xref rid="jia225066-bib-0028" ref-type="ref">28</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">394</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Silva et&#x000a0;al., 2014 <xref rid="jia225066-bib-0060" ref-type="ref">60</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">314</td><td align="left" rowspan="1" colspan="1">SR (CEAT&#x02010;VIH)</td><td align="left" rowspan="1" colspan="1">&#x02265;85</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Silveira et&#x000a0;al., 2014 <xref rid="jia225066-bib-0062" ref-type="ref">62</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">RCT</td><td align="char" char="." rowspan="1" colspan="1">332</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Souza et&#x000a0;al., 2016 <xref rid="jia225066-bib-0076" ref-type="ref">76</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">140</td><td align="left" rowspan="1" colspan="1">SR (CEAT&#x02010;VIH)&#x000a0;&#x0003e;&#x000a0;Withdrawal</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">7</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Teixeira et&#x000a0;al., 2013 <xref rid="jia225066-bib-0052" ref-type="ref">52</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Non&#x02010;RCT longitudinal</td><td align="char" char="." rowspan="1" colspan="1">144</td><td align="left" rowspan="1" colspan="1">Pill count+SR (ACTG)<xref ref-type="fn" rid="jia225066-note-0009">h</xref>
</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Tello&#x02010;Vel&#x000e1;squez et&#x000a0;al., 2015 <xref rid="jia225066-bib-0070" ref-type="ref">70</xref>
</td><td align="left" rowspan="1" colspan="1">Peru</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">389</td><td align="left" rowspan="1" colspan="1">SR (CEAT&#x02010;VIH)</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.74</td><td align="left" rowspan="1" colspan="1">11,295</td></tr><tr><td align="left" rowspan="1" colspan="1">Tietzmann et&#x000a0;al., 2013 <xref rid="jia225066-bib-0053" ref-type="ref">53</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">453</td><td align="left" rowspan="1" colspan="1">SR</td><td align="left" rowspan="1" colspan="1">&#x02265;95</td><td align="left" rowspan="1" colspan="1">3</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Tufano et&#x000a0;al., 2015 <xref rid="jia225066-bib-0071" ref-type="ref">71</xref>
</td><td align="left" rowspan="1" colspan="1">Brazil</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">438</td><td align="left" rowspan="1" colspan="1">SR (SMAQ)</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">7, 90</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.754</td><td align="left" rowspan="1" colspan="1">14,145</td></tr><tr><td align="left" rowspan="1" colspan="1">Varela et&#x000a0;al., 2014 <xref rid="jia225066-bib-0061" ref-type="ref">61</xref>
</td><td align="left" rowspan="1" colspan="1">Chile</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">120</td><td align="left" rowspan="1" colspan="1">SR (Morisky&#x02010;Green&#x02010;Levine)</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">High</td><td align="char" char="." rowspan="1" colspan="1">0.847</td><td align="left" rowspan="1" colspan="1">21,665</td></tr><tr><td align="left" rowspan="1" colspan="1">Varela&#x02010;Ar&#x000e9;valo et&#x000a0;al., 2013 <xref rid="jia225066-bib-0054" ref-type="ref">54</xref>
</td><td align="left" rowspan="1" colspan="1">Colombia</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">127</td><td align="left" rowspan="1" colspan="1">SR (CAT&#x02010;VIH)</td><td align="left" rowspan="1" colspan="1">&#x0003e;90</td><td align="left" rowspan="1" colspan="1">Not reported</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.727</td><td align="left" rowspan="1" colspan="1">12,762</td></tr><tr><td align="left" rowspan="1" colspan="1">Zulliger et&#x000a0;al., 2015 <xref rid="jia225066-bib-0072" ref-type="ref">72</xref>
</td><td align="left" rowspan="1" colspan="1">Dominican Republic</td><td align="left" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">194</td><td align="left" rowspan="1" colspan="1">SR (ACTG)</td><td align="left" rowspan="1" colspan="1">100</td><td align="left" rowspan="1" colspan="1">4</td><td align="left" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">0.722</td><td align="left" rowspan="1" colspan="1">12,756</td></tr></tbody></table><table-wrap-foot><fn id="jia225066-note-0001"><p>ACTG, Aids Clinical Trials Group; CAT&#x02010;VIH, <italic>Cuestionario de adherencia al tratamiento para el VIH/SIDA</italic>; CEAT&#x02010;VIH, <italic>Cuestionario para la Evaluaci&#x000f3;n de la Adhesi&#x000f3;n al Tratamiento Antirretroviral</italic>; MEMS, medication event monitoring system; PMAQ, Patient Medication Adherence Questionnaire; RCT, randomized clinical trials; SMAQ, Simplified Medication Adherence Questionnaire; SR, self&#x02010;report; VAS, visual analogue scale;</p></fn><fn id="jia225066-note-0002"><label>a</label><p>Study countries were categorized according to the income group, as defined by the World Bank for 2017 <xref rid="jia225066-bib-0022" ref-type="ref">22</xref>.</p></fn><fn id="jia225066-note-0003"><label>b</label><p>Study countries were categorized according to the United Nations Human Development Index (HDI) ranking and the Gross National Income (GNI) per capita (based on purchasing power parity in constant 2011 international dollars), as defined by the United Nations Development Programme <xref rid="jia225066-bib-0003" ref-type="ref">3</xref>.</p></fn><fn id="jia225066-note-0004"><label>c</label><p>Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay and Venezuela.</p></fn><fn id="jia225066-note-0005"><label>d</label><p>Argentina, Brazil, Chile, Honduras, Mexico and Peru.</p></fn><fn id="jia225066-note-0006"><label>e</label><p>Argentina, Bolivia, Brazil, Chile, Colombia, Costa Rica, Ecuador, El Salvador, Guatemala, Honduras, Mexico, Nicaragua, Panama, Paraguay, Peru, Uruguay and Venezuela.</p></fn><fn id="jia225066-note-0007"><label>f</label><p>Argentina, Brazil, Dominican Republic, Jamaica, Mexico and Puerto Rico.</p></fn><fn id="jia225066-note-0008"><label>g</label><p>Used two methods to measure adherence, self&#x02010;report or medication withdrawal, to calculate study proportion of participants in optimal adherence.</p></fn><fn id="jia225066-note-0009"><label>h</label><p>Used two methods to measure adherence, self&#x02010;report and pill count, to calculate study proportion of participants in optimal adherence.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap><p>Adherence was most commonly self&#x02010;reported via structured interviews (96.2%). Forty&#x02010;nine studies (92.4%), enrolling 21,974 participants, provided a self&#x02010;reported adherence proportion. Forty&#x02010;seven studies (88.7%) used self&#x02010;report instruments only and one used MEMS only. Five studies (9.4%) used a combination of patient self&#x02010;report, MEMS, pill count and drug refill. The following standardized instruments were used to measure self&#x02010;reported adherence: the AIDS Clinical Trials Group (ACTG) adherence instrument <xref rid="jia225066-bib-0080" ref-type="ref">80</xref>; the CAT&#x02010;VIH &#x02010; <italic>Cuestionario de adherencia al tratamiento para el VIH/SIDA</italic>
<xref rid="jia225066-bib-0081" ref-type="ref">81</xref>; the CEAT&#x02010;VIH &#x02010; <italic>Cuestionario para la Evaluaci&#x000f3;n de la Adhesi&#x000f3;n al Tratamiento Antirretroviral</italic>
<xref rid="jia225066-bib-0082" ref-type="ref">82</xref>; the Morisky, Green &#x00026; Levine Medication Adherence Scale <xref rid="jia225066-bib-0083" ref-type="ref">83</xref>; the PMAQ &#x02010; Patient Medication Adherence Questionnaire <xref rid="jia225066-bib-0084" ref-type="ref">84</xref>; the SMAQ &#x02010; Simplified Medication Adherence Questionnaire <xref rid="jia225066-bib-0085" ref-type="ref">85</xref> and the VPAD&#x02010;24 &#x02010; <italic>Variables psicol&#x000f3;gicas y comportamientos de adhesi&#x000f3;n</italic>
<xref rid="jia225066-bib-0086" ref-type="ref">86</xref>. Twenty&#x02010;five studies (47.2%) did not report the instrument used or the instrument was designed for the study or adapted from other studies.</p><p>Two studies combined two different adherence measures reporting the overall optimal adherence proportion: Teixeira et&#x000a0;al. (2013)<xref rid="jia225066-bib-0052" ref-type="ref">52</xref> (ACTG questionnaire and pill count) and Pac&#x000ed;fico et&#x000a0;al. (2015)<xref rid="jia225066-bib-0073" ref-type="ref">73</xref> (SMAQ questionnaire or drug refill). Balandr&#x000e1;n et&#x000a0;al. (2013) <xref rid="jia225066-bib-0056" ref-type="ref">56</xref>, assessed adherence using the ACTG questionnaire (5 items) and the adherence index, but only the results for the ACTG questionnaire were considered in this meta&#x02010;analysis. Though as a general rule we opted to use reported data from the most objective methods, a few exceptions were made. Campbell et&#x000a0;al. (2010) <xref rid="jia225066-bib-0037" ref-type="ref">37</xref> used both self&#x02010;report (Visual Analogue Scale [VAS]) and pill count for measuring adherence. Although pill count was the most objective measure, the time frame information for it was not available, thus only data from the seven&#x02010;day recall self&#x02010;report measure (VAS) was considered in the analysis. In Souza et&#x000a0;al. (2016) <xref rid="jia225066-bib-0076" ref-type="ref">76</xref>, only the self&#x02010;reported adherence measure was considered because the adherence as measured from medication dispensing data addressed a period greater than three months (the whole study period).</p><p>Studies used different thresholds to define optimal adherence (range: &#x02265;64% to&#x000a0;&#x0003e;&#x000a0;100%). The most common definitions used for optimal adherence were higher than 95% and 100% of prescribed doses (54.7%). Adherence recall time frames varied between the last three days and the last 90&#x000a0;days. Seventeen studies (32.1%) did not clearly report the time frame used.</p><p>Twenty&#x02010;four out of 53 studies evaluated factors associated with adherence using adjusted statistical models. Statistically significant factors (<italic>p</italic>&#x000a0;&#x0003c;&#x000a0;0.05) associated with adherence to ART found by these studies are presented in Table&#x000a0;<xref rid="jia225066-tbl-0002" ref-type="table-wrap">2</xref>. Some factors positively associated with adherence to ART were: high social support <xref rid="jia225066-bib-0032" ref-type="ref">32</xref>, <xref rid="jia225066-bib-0049" ref-type="ref">49</xref>, good relationship with the physician <xref rid="jia225066-bib-0039" ref-type="ref">39</xref>, <xref rid="jia225066-bib-0068" ref-type="ref">68</xref>; satisfaction with the healthcare service <xref rid="jia225066-bib-0032" ref-type="ref">32</xref>, <xref rid="jia225066-bib-0072" ref-type="ref">72</xref>; and use of counselling services <xref rid="jia225066-bib-0038" ref-type="ref">38</xref>. Some factors negatively associated with adherence to ART were: alcohol use or alcohol use disorders <xref rid="jia225066-bib-0027" ref-type="ref">27</xref>, <xref rid="jia225066-bib-0038" ref-type="ref">38</xref>, <xref rid="jia225066-bib-0052" ref-type="ref">52</xref>, <xref rid="jia225066-bib-0064" ref-type="ref">64</xref>, <xref rid="jia225066-bib-0077" ref-type="ref">77</xref>; substance use <xref rid="jia225066-bib-0052" ref-type="ref">52</xref>, <xref rid="jia225066-bib-0072" ref-type="ref">72</xref>, <xref rid="jia225066-bib-0077" ref-type="ref">77</xref>, <xref rid="jia225066-bib-0078" ref-type="ref">78</xref>; high pill burden <xref rid="jia225066-bib-0027" ref-type="ref">27</xref>, <xref rid="jia225066-bib-0047" ref-type="ref">47</xref>, <xref rid="jia225066-bib-0062" ref-type="ref">62</xref>; depression symptoms <xref rid="jia225066-bib-0061" ref-type="ref">61</xref>, <xref rid="jia225066-bib-0062" ref-type="ref">62</xref>, <xref rid="jia225066-bib-0071" ref-type="ref">71</xref>; unemployment or irregular employment <xref rid="jia225066-bib-0027" ref-type="ref">27</xref>, <xref rid="jia225066-bib-0062" ref-type="ref">62</xref>; and high or detectable HIV viral load <xref rid="jia225066-bib-0062" ref-type="ref">62</xref>, <xref rid="jia225066-bib-0071" ref-type="ref">71</xref>.</p><table-wrap id="jia225066-tbl-0002" xml:lang="en" orientation="portrait" position="float"><label>Table 2</label><caption><p>Factors associated with adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean, for 24 studies with available data, 2005&#x02013;2016</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><thead valign="top"><tr style="border-bottom:solid 1px #000000"><th align="left" valign="top" rowspan="1" colspan="1">Source</th><th align="left" valign="top" rowspan="1" colspan="1">Factors associated with adherence</th></tr></thead><tbody><tr><td align="left" rowspan="1" colspan="1">Allen et&#x000a0;al., 2011 <xref rid="jia225066-bib-0038" ref-type="ref">38</xref>
</td><td align="left" rowspan="1" colspan="1">
Use of a counselling service (AOR<bold>&#x000a0;=&#x000a0;</bold>3.20; 95% CI: 1.55<bold>&#x02013;</bold>6.61; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.002)<break/>
Revelation of HIV status without consent (AOR<bold>&#x000a0;=&#x000a0;</bold>2.31; 95% CI: 1.13<bold>&#x02013;</bold>4.74; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.023)<break/>
Alcohol consumption (AOR<bold>&#x000a0;=&#x000a0;</bold>0.47; 95% CI: 0.23<bold>&#x02013;</bold>0.96; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.039)<break/>
Side effects (AOR<bold>&#x000a0;=&#x000a0;</bold>0.32; 95% CI: 0.15<bold>&#x02013;</bold>0.68; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.003)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Aragon&#x000e9;s et&#x000a0;al., 2011 <xref rid="jia225066-bib-0039" ref-type="ref">39</xref>
</td><td align="left" rowspan="1" colspan="1">
Communication with the physician (AOR<bold>&#x000a0;=&#x000a0;</bold>1.457; 95% CI: 1.010<bold>&#x02013;</bold>2.103; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.044)<break/>
Change in treatment (AOR<bold>&#x000a0;=&#x000a0;</bold>1.597; 95% CI: 1.083<bold>&#x02013;</bold>2.358; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.018)<break/>
Memory (AOR<bold>&#x000a0;=&#x000a0;</bold>3.175; 95% CI: 2.112<bold>&#x02013;</bold>4.774; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.000)<break/>
Self&#x02010;efficacy (AOR<bold>&#x000a0;=&#x000a0;</bold>2.976; 95% CI: 1.999<bold>&#x02013;</bold>4.433; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.000)<break/>
Commitment to treatment (AOR<bold>&#x000a0;=&#x000a0;</bold>1.597; 95% CI: 1.093<bold>&#x02013;</bold>2.334; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.016)<break/>
Confidence in treatment (AOR<bold>&#x000a0;=&#x000a0;</bold>1.817; 95% CI: 1.245<bold>&#x02013;</bold>2.650; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.002)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Arrivillaga et&#x000a0;al., 2009 <xref rid="jia225066-bib-0036" ref-type="ref">36</xref>
</td><td align="left" rowspan="1" colspan="1">Membership in the subsidized national health care plan<xref ref-type="fn" rid="jia225066-note-0011">a</xref> or being uninsured (AOR<bold>&#x000a0;=&#x000a0;</bold>3.478; 95% CI: 1.957&#x02013;6.181; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.0001) when compared to the contributive plan.</td></tr><tr><td align="left" rowspan="1" colspan="1">Biello et&#x000a0;al., 2016 <xref rid="jia225066-bib-0078" ref-type="ref">78</xref>
</td><td align="left" rowspan="1" colspan="1">
Age (AOR<bold>&#x000a0;=&#x000a0;</bold>1.02; 95% CI: 1.00<bold>&#x02013;</bold>1.03; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.04)<break/>
Hard drug use during sex (AOR<bold>&#x000a0;=&#x000a0;</bold>0.72; 95% CI: 0.53<bold>&#x02013;</bold>0.96; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.03)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Bonolo et&#x000a0;al., 2005 <xref rid="jia225066-bib-0027" ref-type="ref">27</xref>
</td><td align="left" rowspan="1" colspan="1">
(Nonadherence)<break/>
Unemployment (ARH<bold>&#x000a0;=&#x000a0;</bold>2.17; 95% CI: 1.19&#x02013;3.96; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.011)<break/>
Alcohol use (ARH<bold>&#x000a0;=&#x000a0;</bold>2.27; 95% CI: 1.58&#x02013;3.25; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.001)<break/>
Self&#x02010;report of three or more adverse reactions (ARH<bold>&#x000a0;=&#x000a0;</bold>1.64; 95% CI: 1.09&#x02013;2.48; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.017)<break/>
Number of pills per day (ARH<bold>&#x000a0;=&#x000a0;</bold>2.04; 95% CI: 1.11&#x02013;3.76; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.02)<break/>
Switch in antiretroviral regimen (ARH<bold>&#x000a0;=&#x000a0;</bold>2.72; 95% CI: 1.84&#x02013;4.03; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.001)<break/>
Use of more than one health service (RH<bold>&#x000a0;=&#x000a0;</bold>0.54; 95% CI: 0.36&#x02013;0.80; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.002)<break/>
Longer time between HIV test and 1st prescription (ARH<bold>&#x000a0;=&#x000a0;</bold>2.27; 95% CI: 1.52&#x02013;3.40; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.001)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Calvetti et&#x000a0;al., 2014 <xref rid="jia225066-bib-0057" ref-type="ref">57</xref>
</td><td align="left" rowspan="1" colspan="1">
Social class (middle) (AOR<bold>&#x000a0;=&#x000a0;</bold>3.5250; 95% CI: 1.229<bold>&#x02013;</bold>10.080; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.019)<break/>
Perceived HIV stage (symptomatic) (AOR<bold>&#x000a0;=&#x000a0;</bold>0.346; 95% CI: 0.138<bold>&#x02013;</bold>0.871; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.024)<break/>
WHOQOL&#x02010;HIV bref<xref ref-type="fn" rid="jia225066-note-0012">b</xref> domain I/physical<xref ref-type="fn" rid="jia225066-note-0013">c</xref> (AOR<bold>&#x000a0;=&#x000a0;</bold>1.276; 95% CI: 1.010<bold>&#x02013;</bold>1.613; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.041)<break/>
WHOQOL&#x02010;HIV bref<xref ref-type="fn" rid="jia225066-note-0012">b</xref> domain V/environment<xref ref-type="fn" rid="jia225066-note-0013">c</xref> (AOR<bold>&#x000a0;=&#x000a0;</bold>1.415; 95% CI: 1.158<bold>&#x02013;</bold>1.728; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.001)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Carvalho et&#x000a0;al., 2007 <xref rid="jia225066-bib-0032" ref-type="ref">32</xref>
</td><td align="left" rowspan="1" colspan="1">
(Nonadherence)<break/>
Lower educational level (AOR<bold>&#x000a0;=&#x000a0;</bold>18.4; 95% CI: 2.9<bold>&#x02013;</bold>118.8; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.002)<break/>
Profession (AOR<bold>&#x000a0;=&#x000a0;</bold>0.2; 95% CI: 0.0<bold>&#x02013;</bold>0.9; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.047)<break/>
Income (AOR<bold>&#x000a0;=&#x000a0;</bold>1.0; 95% CI: 1.0<bold>&#x02013;</bold>1.0; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.007)<break/>
High social support (AOR<bold>&#x000a0;=&#x000a0;</bold>10.6; 95% CI: 1.4<bold>&#x02013;</bold>79.1; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.022)<break/>
Satisfaction with the service at the pharmacy (AOR<bold>&#x000a0;=&#x000a0;</bold>32.5; 95% CI: 4.6<bold>&#x02013;</bold>227.9; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.000)<break/>
Healthcare reference centre in <italic>Plano Piloto</italic> (an urban planned location vs. unplanned) (AOR<bold>&#x000a0;=&#x000a0;</bold>0.2; 95% CI: 0.1<bold>&#x02013;</bold>0.7; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.014)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Casotti et&#x000a0;al., 2011 <xref rid="jia225066-bib-0041" ref-type="ref">41</xref>
</td><td align="left" rowspan="1" colspan="1">
Higher educational level (AOR<bold>&#x000a0;=&#x000a0;</bold>1.40; 95% CI: 1.10<bold>&#x02013;</bold>1.78; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.006)<break/>
longer duration of undetectable viral load (AOR<bold>&#x000a0;=&#x000a0;</bold>1.03; 95% CI: 1.00<bold>&#x02013;</bold>1.06; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.02)
</td></tr><tr><td align="left" rowspan="1" colspan="1">De Boni et&#x000a0;al., 2016 <xref rid="jia225066-bib-0077" ref-type="ref">77</xref>
</td><td align="left" rowspan="1" colspan="1">
(Nonadherence &#x02010; missed doses)<break/>
Substance use (<italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.001):<break/>
alcohol use compared to no substance use (AOR<bold>&#x000a0;=&#x000a0;</bold>2.46; 95% CI: 1.99&#x02013;3.05)<break/>
illicit drug use compared to no substance use (AOR<bold>&#x000a0;=&#x000a0;</bold>3.57; 95% CI: 2.02&#x02013;6.30)<break/>
using both alcohol and illicit drugs compared to no substance use (AOR<bold>&#x000a0;=&#x000a0;</bold>4.98; 95% CI: 3.19&#x02013;7.79)<break/>
HIV transmission mode (<italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.001):<break/>
homosexual vs. heterosexual (AOR<bold>&#x000a0;=&#x000a0;</bold>0.88; 95% CI: 0.67<bold>&#x02013;</bold>1.16)<break/>
IDU vs. heterosexual (AOR<bold>&#x000a0;=&#x000a0;</bold>2.46; 95% CI: 1.04<bold>&#x02013;</bold>5.83)<break/>
others vs. heterosexual (AOR<bold>&#x000a0;=&#x000a0;</bold>1.44; 95% CI: 1.05<bold>&#x02013;</bold>1.98)<break/>
Age (per ten years increase) (AOR<bold>&#x000a0;=&#x000a0;</bold>0.88; 95% CI: 0.80<bold>&#x02013;</bold>0.98; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.02)<break/>
Study site (AOR<bold>&#x000a0;=&#x000a0;</bold>1.87; 95% CI: 1.17&#x02013;3.01 for IHSS/HE&#x02010;Honduras vs. FH&#x02010;Argentina<break/>
AOR<bold>&#x000a0;=&#x000a0;</bold>0.08; 95% CI: 0.04&#x02013;0.16 for INCMNSZ&#x02010;Mexico vs. FH&#x02010;Argentina; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.001)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Drachler et&#x000a0;al., 2016 <xref rid="jia225066-bib-0075" ref-type="ref">75</xref>
</td><td align="left" rowspan="1" colspan="1">
(Nonadherence)<break/>
SEA&#x02010;ART<xref ref-type="fn" rid="jia225066-note-0014">d</xref> score (per each unit increase) (AOR<bold>&#x000a0;=&#x000a0;</bold>0.92; 95% CI: 0.90<bold>&#x02013;</bold>0.95; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.002)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Ferro et&#x000a0;al., 2015 <xref rid="jia225066-bib-0064" ref-type="ref">64</xref>
</td><td align="left" rowspan="1" colspan="1">
Having an alcohol use disorder with optimal adherence (AOR<bold>&#x000a0;=&#x000a0;</bold>0.427; 95% CI: 0.187&#x02013;0.976; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.044)<break/>
Having an alcohol use disorder with perfect adherence (AOR<bold>&#x000a0;=&#x000a0;</bold>0.552; 95% CI: 0.327&#x02013;0.930; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.026)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Gutierrez et&#x000a0;al., 2012 <xref rid="jia225066-bib-0047" ref-type="ref">47</xref>
</td><td align="left" rowspan="1" colspan="1">
Having symptoms prior to ART (<italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.039)<break/>
Taking fewer ART pills (<italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.003)<break/>
Not missing medical appointments (<italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.0001)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Hanif et&#x000a0;al., 2013 <xref rid="jia225066-bib-0049" ref-type="ref">49</xref>
</td><td align="left" rowspan="1" colspan="1">
Having one child (compared to 0 or &#x02265;2) (AOR<bold>&#x000a0;=&#x000a0;</bold>2.29; 95% CI: 1.33<bold>&#x02013;</bold>3.94; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.003)<break/>
High social support (AOR<bold>&#x000a0;=&#x000a0;</bold>2.85; 95% CI: 1.50<bold>&#x02013;</bold>5.41; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.001)<break/>
High asset index (AOR<bold>&#x000a0;=&#x000a0;</bold>2.47; 95% CI: 1.79<bold>&#x02013;</bold>3.40; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.000)<break/>
Gender female (AOR<bold>&#x000a0;=&#x000a0;</bold>0.58; 95% CI: 0.38<bold>&#x02013;</bold>0.88; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.011)
</td></tr><tr><td align="left" rowspan="1" colspan="1">P&#x000e9;rez&#x02010;Salgado et&#x000a0;al., 2015 <xref rid="jia225066-bib-0068" ref-type="ref">68</xref>
</td><td align="left" rowspan="1" colspan="1">
(Low adherence)<break/>
Patient dissatisfaction about relationship with the physician (AOR<bold>&#x000a0;=&#x000a0;</bold>1.90; 95% CI: 1.01<bold>&#x02013;</bold>3.57; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.046)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Pi&#x000f1;a L&#x000f3;pez et&#x000a0;al., 2008 <xref rid="jia225066-bib-0034" ref-type="ref">34</xref>
</td><td align="left" rowspan="1" colspan="1">The combination of intermediate levels of stress associated with tolerance to ambiguity and low levels of depression (<italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.027)</td></tr><tr><td align="left" rowspan="1" colspan="1">Remien et&#x000a0;al., 2007 <xref rid="jia225066-bib-0031" ref-type="ref">31</xref>
</td><td align="left" rowspan="1" colspan="1">
(Nonadherence)<break/>
Sexual orientation (heterosexual vs. homosexual/bisexual) (AOR<bold>&#x000a0;=&#x000a0;</bold>2.69; 95% CI: 1.08&#x02013;6.66; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05)<break/>
Difficulty to tailoring therapeutic regimen to daily routine (AOR<bold>&#x000a0;=&#x000a0;</bold>2.56; 95% CI: 1.07&#x02013;6.14; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05)<break/>
Loss of appetite in the last month (AOR<bold>&#x000a0;=&#x000a0;</bold>3.56; 95% CI: 1.31&#x02013;9.62; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Silveira et&#x000a0;al., 2014 <xref rid="jia225066-bib-0062" ref-type="ref">62</xref>
</td><td align="left" rowspan="1" colspan="1">
No regular employment (ARR<bold>&#x000a0;=&#x000a0;</bold>0.91; 95% CI: 0.82&#x02013;1.00; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.05)<break/>
Detectable plasma viral load (ARR<bold>&#x000a0;=&#x000a0;</bold>0.83; 95% CI: 0.73&#x02013;0.95; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.01)<break/>
Depressive symptoms (ARR<bold>&#x000a0;=&#x000a0;</bold>0.99; 95% CI: 0.99&#x02013;1.00; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.04)<break/>
Number of tablets daily (ARR<bold>&#x000a0;=&#x000a0;</bold>0.96; 95% CI: 0.93&#x02013;0.98; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.01)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Teixeira et&#x000a0;al., 2013 <xref rid="jia225066-bib-0052" ref-type="ref">52</xref>
</td><td align="left" rowspan="1" colspan="1">
Intensity of alcohol use (AOR<bold>&#x000a0;=&#x000a0;</bold>3.29; 95% CI: 1.83&#x02013;5.92; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.001)<break/>
Use of alcohol and multiple substances (AOR<bold>&#x000a0;=&#x000a0;</bold>5.99; 95% CI: 1.78&#x02013;20.28; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.004)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Tello&#x02010;Vel&#x000e1;squez et&#x000a0;al., 2015 <xref rid="jia225066-bib-0070" ref-type="ref">70</xref>
</td><td align="left" rowspan="1" colspan="1">
(Nonadherence)<break/>
Moderate/severe poor quality of sleep (APR<bold>&#x000a0;=&#x000a0;</bold>1.34; 95% CI: 1.17<bold>&#x02013;</bold>1.54; <italic>p&#x000a0;</italic>=<italic>&#x000a0;</italic>0.001)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Tietzmann et&#x000a0;al., 2013 <xref rid="jia225066-bib-0053" ref-type="ref">53</xref>
</td><td align="left" rowspan="1" colspan="1">
Gender male (APR<bold>&#x000a0;=&#x000a0;</bold>1.37; 1.24<bold>&#x02013;</bold>1.52; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.000)<break/>
Low and moderate clinical status (compared to severe) (APR<bold>&#x000a0;=&#x000a0;</bold>1.18; 95% CI: 1.04<bold>&#x02013;</bold>1.35; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.009)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Tufano et&#x000a0;al., 2015 <xref rid="jia225066-bib-0071" ref-type="ref">71</xref>
</td><td align="left" rowspan="1" colspan="1">
Nonadherence in last seven days:<break/>
Age in years (AOR<bold>&#x000a0;=&#x000a0;</bold>0.96; 95% CI: 0.93<bold>&#x02013;</bold>0.98; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.01)<break/>
Hamilton Depression Rating Scale (AOR<bold>&#x000a0;=&#x000a0;</bold>1.04; 95% CI: 1.01<bold>&#x02013;</bold>1.07; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.01)<break/>
Viral load (AOR<bold>&#x000a0;=&#x000a0;</bold>1.21; 95% CI: 1.03<bold>&#x02013;</bold>1.42; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05)<break/>
Nonadherence in last 90&#x000a0;days:<break/>
Age in years (AOR<bold>&#x000a0;=&#x000a0;</bold>1.02; 95% CI: 1.00<bold>&#x02013;</bold>1.05; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05)<break/>
Viral load (AOR<bold>&#x000a0;=&#x000a0;</bold>1.21; 95% CI: 1.03<bold>&#x02013;</bold>1.42; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05)<break/>
Heterosexual HIV transmission mode (compared to homo/bisexual) (AOR<bold>&#x000a0;=&#x000a0;</bold>0.52; 95% CI: 0.28<bold>&#x02013;</bold>0.96; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05)<break/>
Unknown HIV transmission mode (compared to homo/bisexual) (AOR<bold>&#x000a0;=&#x000a0;</bold>0.10; 95% CI: 0.01<bold>&#x02013;</bold>0.88; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05)<break/>
CD4&#x000a0;+&#x000a0; cell count (AOR<bold>&#x000a0;=&#x000a0;</bold>0.99; 95% CI: 0.99<bold>&#x02013;</bold>1.00; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Varela et&#x000a0;al., 2014 <xref rid="jia225066-bib-0061" ref-type="ref">61</xref>
</td><td align="left" rowspan="1" colspan="1">
Nonadherence:<break/>
Moderate&#x02010;severe depressive symptoms [Exp(B) <bold>&#x000a0;=&#x000a0;</bold>3.08; 95% CI: 1.08<bold>&#x02013;</bold>8.80; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.023]
</td></tr><tr><td align="left" rowspan="1" colspan="1">Varela&#x02010;Ar&#x000e9;valo et&#x000a0;al., 2013 <xref rid="jia225066-bib-0054" ref-type="ref">54</xref>
</td><td align="left" rowspan="1" colspan="1">
Barriers to treatment (AOR<bold>&#x000a0;=&#x000a0;</bold>7.9; 95% CI: 2.04<bold>&#x02013;</bold>30.59; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.003)<break/>
Men with no family member with HIV (AOR<bold>&#x000a0;=&#x000a0;</bold>0.10; 95% CI: 0.01<bold>&#x02013;</bold>0.73; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.023)<break/>
Women with no family member with HIV (AOR<bold>&#x000a0;=&#x000a0;</bold>0.05; 95% CI: 0.00<bold>&#x02013;</bold>0.73; <italic>p</italic>
<bold>&#x000a0;=&#x000a0;</bold>0.028)
</td></tr><tr><td align="left" rowspan="1" colspan="1">Zulliger et&#x000a0;al., 2015 <xref rid="jia225066-bib-0072" ref-type="ref">72</xref>
</td><td align="left" rowspan="1" colspan="1">
Nonadherence:<break/>
&#x02018;Female sex worker&#x02019;&#x02010;related discrimination (AOR<bold>&#x000a0;=&#x000a0;</bold>3.24; 95% CI: 1.28<bold>&#x02013;</bold>8.20; <italic>p&#x000a0;</italic>&#x02264;<italic>&#x000a0;</italic>0.05)<break/>
Use of any drug (AOR<bold>&#x000a0;=&#x000a0;</bold>2.41; 95% CI: 1.09<bold>&#x02013;</bold>5.34; <italic>p&#x000a0;</italic>&#x02264;<italic>&#x000a0;</italic>0.01)<break/>
Worked in a &#x02018;Female sex worker&#x02019; establishment (AOR<bold>&#x000a0;=&#x000a0;</bold>2.35; 95% CI: 1.20<bold>&#x02013;</bold>4.60; <italic>p&#x000a0;</italic>&#x02264;<italic>&#x000a0;</italic>0.05)<break/>
Internalized stigma related to female sex work (AOR<bold>&#x000a0;=&#x000a0;</bold>1.09; 95% CI: 1.02<bold>&#x02013;</bold>1.16; <italic>p&#x000a0;</italic>&#x02264;<italic>&#x000a0;</italic>0.05)<break/>
Positive perceptions of HIV providers (AOR<bold>&#x000a0;=&#x000a0;</bold>0.91; 95% CI: 0.85<bold>&#x02013;</bold>0.98; <italic>p&#x000a0;</italic>&#x02264;<italic>&#x000a0;</italic>0.05)
</td></tr></tbody></table><table-wrap-foot><fn id="jia225066-note-0010"><p>AOR, adjusted odds ratio; APR, adjusted prevalence ratio; ARR, adjusted relative risk; ARH, adjusted relative hazard; IDU, injection drug use.</p></fn><fn id="jia225066-note-0011"><label>a</label><p>General System of Social Security in Health (<italic>Sistema General de Seguridad Social en Salud</italic>, SGSSS &#x02010; Colombia).</p></fn><fn id="jia225066-note-0012"><label>b</label><p>WHOQOL&#x02010;HIV bref is a shorter version of the original instrument WHOQOL&#x02010;HIV, a multi&#x02010;dimensional instrument designed to assess the quality of life of people infected with human immunodeficiency virus (HIV).</p></fn><fn id="jia225066-note-0013"><label>c</label><p>Domain I of WHOQOL&#x02010;HIV bref includes physical pain, physical problem, energy and sleep quality; and domain V includes physical safety, housing, finance, care (access to quality health care and social services), information, leisure time, physical environment (pollution/noise/transit/climate) and transport.</p></fn><fn id="jia225066-note-0014"><label>d</label><p>The scale of Self&#x02010;efficacy Expectations of Adherence to Antiretroviral Treatment (SEA&#x02010;ART) assesses patients&#x02019; expectations of their own ability to follow the antiretroviral prescription in 21 high&#x02010;risk situations for non&#x02010;adherence to ART.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec><sec id="jia225066-sec-0018"><label>3.2</label><title>Risk of Bias</title><p>The results of the risk of bias assessment for each study included in the meta&#x02010;analysis are shown in Figure&#x000a0;<xref rid="jia225066-fig-0002" ref-type="fig">2</xref>. The risk of selection biases due to the inadequate selection of participants was high in 43 studies, low in three and unclear in seven. The risk of selection biases due to the inadequate confirmation and consideration of confounding variables during the design and analysis phases was low in 36 studies, but high in the remaining 17. The risk of performance biases caused by inadequate measurements of exposure was low in 50 studies, high in two and unclear in one. The risk of attrition biases caused by the inadequate handling of incomplete outcome data was low in 47 studies and high in the remaining six. The risk of selective reporting bias was low in all studies.</p><fig fig-type="Figure" xml:lang="en" id="jia225066-fig-0002" orientation="portrait" position="float"><label>Figure 2</label><caption><p>Risk of bias of studies included in the meta&#x02010;analysis of adherence to antiretroviral therapy for <styled-content style="fixed-case">HIV</styled-content>/<styled-content style="fixed-case">AIDS</styled-content> in Latin America and the Caribbean, 2005&#x02013;2016, presented as percentages across all included studies.</p></caption><graphic id="nlm-graphic-3" xlink:href="JIA2-21-e25066-g002"/></fig></sec><sec id="jia225066-sec-0019"><label>3.3</label><title>Meta&#x02010;analysis</title><p>The overall pooled adherence was estimated in 70% (95% CI: 63<bold>&#x02013;</bold>76; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>98%) (Figure&#x000a0;<xref rid="jia225066-fig-0003" ref-type="fig">3</xref>). Results differed when we stratified studies by the four pre&#x02010;defined time frames: last 3<bold>&#x02013;</bold>4&#x000a0;days, last 7 days, last 30&#x000a0;days and last 90&#x000a0;days. The pooled estimate for the shortest period was significantly 7 higher and somewhat less heterogeneous (80%; 95% CI: 74<bold>&#x02013;</bold>85; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold> =</bold> 93%) than for the longest period (55%; 95% CI: 26<bold>&#x02013;</bold>81; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>96%) (Figure&#x000a0;<xref rid="jia225066-fig-0004" ref-type="fig">4</xref>). We also recalculated the pooled proportion according to the location/country, and in Brazil, where most of studies were conducted (45.3%), the adherence estimate was 64% (95% CI: 54<bold>&#x02013;</bold>73; <italic>I</italic>
<sup>2</sup>
<bold>&#x000a0;=&#x000a0;</bold>98%) (Figure&#x000a0;<xref rid="jia225066-fig-0005" ref-type="fig">5</xref>).</p><fig fig-type="Figure" xml:lang="en" id="jia225066-fig-0003" orientation="portrait" position="float"><label>Figure 3</label><caption><p>Pooled proportion of <styled-content style="fixed-case">PLHIV</styled-content> adhering to antiretroviral therapy in Latin America and Caribbean, 2005&#x02013;2016. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <italic>I</italic>
<sup><italic>2</italic></sup>, the percentage of total variation across studies that is due to heterogeneity rather than chance; &#x003c4;<sup>2</sup>, tau&#x02010;squared is an estimate of the between&#x02010;study variance; <italic>p</italic>,<italic> p</italic>&#x02010;value.</p></caption><graphic id="nlm-graphic-5" xlink:href="JIA2-21-e25066-g003"/></fig><fig fig-type="Figure" xml:lang="en" id="jia225066-fig-0004" orientation="portrait" position="float"><label>Figure 4</label><caption><p>Pooled proportion of <styled-content style="fixed-case">PLHIV</styled-content> adhering to <styled-content style="fixed-case">ART</styled-content> in <styled-content style="fixed-case">LAC</styled-content> by adherence recall time frame, 2005&#x02013;2016. (a) 3&#x02013;4&#x000a0;days; (b) seven days; (c) 30&#x000a0;days, (d) 90&#x000a0;days. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <italic>I</italic>
<sup><italic>2</italic></sup>, the percentage of total variation across studies that is due to heterogeneity rather than chance; &#x003c4;<sup>2</sup>, tau&#x02010;squared is an estimate of the between&#x02010;study variance; <italic>p</italic>,<italic> p</italic>&#x02010;value.</p></caption><graphic id="nlm-graphic-7" xlink:href="JIA2-21-e25066-g004"/></fig><fig fig-type="Figure" xml:lang="en" id="jia225066-fig-0005" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Pooled proportion of <styled-content style="fixed-case">PLHIV</styled-content> adhering to <styled-content style="fixed-case">ART</styled-content> in Brazil, 2005&#x02013;2016. <styled-content style="fixed-case">CI</styled-content>, confidence interval; <italic>I</italic>
<sup><italic>2</italic></sup>, the percentage of total variation across studies that is due to heterogeneity rather than chance; &#x003c4;<sup>2</sup>, tau&#x02010;squared is an estimate of the between&#x02010;study variance; <italic>p</italic>,<italic> p</italic>&#x02010;value.</p></caption><graphic id="nlm-graphic-9" xlink:href="JIA2-21-e25066-g005"/></fig><p>Results of the subgroup analysis are shown in Table&#x000a0;<xref rid="jia225066-tbl-0003" ref-type="table-wrap">3</xref>. Studies conducted in low or lower middle income countries showed a higher pooled adherence (83%; 95% CI: 63<bold>&#x02013;</bold>93; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>81%) than in middle income countries (70%; 95% CI: 62<bold>&#x02013;</bold>77; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>98%). In countries with a lower HDI (&#x0003c;0.754), pooled adherence was higher (75%; 95% CI:64<bold>&#x02013;</bold>84; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>99%) than in countries with a higher HDI (66%; 95% CI: 57<bold>&#x02013;</bold>74; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>98%). Similarly, in countries with a lower GNI per capita (&#x0003c;$ 14,145) the pooled adherence was higher (75%; 95% CI: 65<bold>&#x02013;</bold>83; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>99%) than in countries with a higher GNI per capita (65%; 95% CI: 55<bold>&#x02013;</bold>74; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>98%). Studies addressing only ART na&#x000ef;ve participants had lower pooled adherence (56%; 95% CI: 33<bold>&#x02013;</bold>78; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>75%) than those including treatment experienced participants (69%; 95% CI: 62<bold>&#x02013;</bold>75; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>98%). The pooled proportion of adherence for studies using patient's self&#x02010;report was 71% (95% CI: 64<bold>&#x02013;</bold>77; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>99%), quite similar to the overall results as expected given that self&#x02010;report was the most frequent tool used to measure adherence (96.2%).</p><table-wrap id="jia225066-tbl-0003" xml:lang="en" orientation="portrait" position="float"><label>Table 3</label><caption><p>Subgroup analysis of studies included in the meta&#x02010;analysis of adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean, 2005&#x02013;2016</p></caption><table frame="hsides" rules="groups"><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><col style="border-right:solid 1px #000000" span="1"/><tbody><tr style="border-bottom:solid 1px #000000"><td align="left" rowspan="2" colspan="1">Analysis group</td><td align="char" rowspan="2" colspan="1">No of Studies</td><td align="char" rowspan="2" colspan="1">Sample size</td><td align="char" rowspan="2" colspan="1">Pooled Adherence (95% CI)</td><td align="char" colspan="2" style="border-bottom:solid 1px #000000" rowspan="1">Tests for Heterogeneity</td></tr><tr style="border-bottom:solid 1px #000000"><td align="char" rowspan="1" colspan="1">
<italic>p&#x02010;</italic>value<break/>
(Q Statistic)<xref ref-type="fn" rid="jia225066-note-0021">f</xref>
</td><td align="char" rowspan="1" colspan="1">
<italic>I</italic>
<sup><italic>2</italic></sup> (%)</td></tr><tr><td align="left" rowspan="1" colspan="1">Overall</td><td align="char" char="." rowspan="1" colspan="1">53</td><td align="char" char="." rowspan="1" colspan="1">22603</td><td align="char" char=" " rowspan="1" colspan="1">0.70 (0.64, 0.75)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" colspan="6" rowspan="1">Time frame</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">3<bold>&#x02013;</bold>4&#x000a0;days</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">4707</td><td align="char" char=" " rowspan="1" colspan="1">0.80 (0.74, 0.85)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">93</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">7&#x000a0;days</td><td align="char" char="." rowspan="1" colspan="1">13</td><td align="char" char="." rowspan="1" colspan="1">6853</td><td align="char" char=" " rowspan="1" colspan="1">0.71 (0.57, 0.82)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">30&#x000a0;days</td><td align="char" char="." rowspan="1" colspan="1">15</td><td align="char" char="." rowspan="1" colspan="1">8348</td><td align="char" char=" " rowspan="1" colspan="1">0.73 (0.58, 0.85)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">99</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">90&#x000a0;days</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">948</td><td align="char" char=" " rowspan="1" colspan="1">0.55 (0.26, 0.81)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">96</td></tr><tr><td align="left" colspan="6" rowspan="1">Location/country</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Brazil</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">5712</td><td align="char" char=" " rowspan="1" colspan="1">0.64 (0.54, 0.73)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">SA (Chile, Colombia, Peru)</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">3754</td><td align="char" char=" " rowspan="1" colspan="1">0.71 (0.49, 0.87)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">99</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">CA/Caribbean (Cuba, DR, Guatemala, Haiti, Jamaica)</td><td align="char" char="." rowspan="1" colspan="1">7</td><td align="char" char="." rowspan="1" colspan="1">2100</td><td align="char" char=" " rowspan="1" colspan="1">0.79 (0.73, 0.85)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">80</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">NA (Mexico, Puerto Rico)</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">2980</td><td align="char" char=" " rowspan="1" colspan="1">0.79 (0.47, 0.94)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Multi&#x02010;site</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">8057</td><td align="char" char=" " rowspan="1" colspan="1">0.66 (0.44, 0.82)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">100</td></tr><tr><td align="left" colspan="6" rowspan="1">Study period</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02264;2005</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">1396</td><td align="char" char=" " rowspan="1" colspan="1">0.68 (0.39, 0.87)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">2006<bold>&#x02013;</bold>2010</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">7328</td><td align="char" char=" " rowspan="1" colspan="1">0.71 (0.60, 0.79)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">97</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;2011</td><td align="char" char="." rowspan="1" colspan="1">12</td><td align="char" char="." rowspan="1" colspan="1">10025</td><td align="char" char=" " rowspan="1" colspan="1">0.66 (0.45, 0.82)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">99</td></tr><tr><td align="left" colspan="6" rowspan="1">Study design</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Cross&#x02010;sectional</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">19257</td><td align="char" char=" " rowspan="1" colspan="1">0.69 (0.62, 0.76)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">99</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Longitudinal</td><td align="char" char="." rowspan="1" colspan="1">6</td><td align="char" char="." rowspan="1" colspan="1">2405</td><td align="char" char=" " rowspan="1" colspan="1">0.75 (0.38, 0.94)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">RCT</td><td align="char" char="." rowspan="1" colspan="1">4</td><td align="char" char="." rowspan="1" colspan="1">941</td><td align="char" char=" " rowspan="1" colspan="1">0.66 (0.39, 0.86)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">94</td></tr><tr><td align="left" colspan="6" rowspan="1">Country's income level<xref ref-type="fn" rid="jia225066-note-0016">a</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Low/Lower middle</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">804</td><td align="char" char=" " rowspan="1" colspan="1">0.83 (0.63, 0.93)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">81</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Upper middle</td><td align="char" char="." rowspan="1" colspan="1">43</td><td align="char" char="." rowspan="1" colspan="1">13426</td><td align="char" char=" " rowspan="1" colspan="1">0.70 (0.62, 0.77)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">High</td><td align="char" rowspan="1" colspan="1">2<xref ref-type="fn" rid="jia225066-note-0018">c</xref>
</td><td align="char" char="." rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Mix</td><td align="char" char="." rowspan="1" colspan="1">5</td><td align="char" char="." rowspan="1" colspan="1">8057</td><td align="char" char=" " rowspan="1" colspan="1">0.66 (0.44, 0.82)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">100</td></tr><tr><td align="left" colspan="6" rowspan="1">HDI<xref ref-type="fn" rid="jia225066-note-0017">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;0.754</td><td align="char" char="." rowspan="1" colspan="1">21</td><td align="char" char="." rowspan="1" colspan="1">12736</td><td align="char" char=" " rowspan="1" colspan="1">0.75 (0.64, 0.84)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">99</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;0.754</td><td align="char" char="." rowspan="1" colspan="1">31</td><td align="char" char="." rowspan="1" colspan="1">9671</td><td align="char" char=" " rowspan="1" colspan="1">0.66 (0.57, 0.74)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" colspan="6" rowspan="1">GNI per capita<xref ref-type="fn" rid="jia225066-note-0017">b</xref>
</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;14145</td><td align="char" char="." rowspan="1" colspan="1">23</td><td align="char" char="." rowspan="1" colspan="1">13791</td><td align="char" char=" " rowspan="1" colspan="1">0.75 (0.65, 0.83)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">99</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x02265;14145</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">8616</td><td align="char" char=" " rowspan="1" colspan="1">0.65 (0.55, 0.74)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" colspan="6" rowspan="1">Sites</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Single</td><td align="char" char="." rowspan="1" colspan="1">27</td><td align="char" char="." rowspan="1" colspan="1">6579</td><td align="char" char=" " rowspan="1" colspan="1">0.65 (0.52, 0.76)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Multi</td><td align="char" char="." rowspan="1" colspan="1">23</td><td align="char" char="." rowspan="1" colspan="1">11585</td><td align="char" char=" " rowspan="1" colspan="1">0.77 (0.70, 0.82)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">96</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Online</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">4440</td><td align="char" char=" " rowspan="1" colspan="1">0.55 (0.31, 0.76)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" colspan="6" rowspan="1">Treatment experience</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Na&#x000ef;ve</td><td align="char" char="." rowspan="1" colspan="1">3</td><td align="char" char="." rowspan="1" colspan="1">510</td><td align="char" char=" " rowspan="1" colspan="1">0.56 (0.33, 0.78)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">75</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Experienced</td><td align="char" char="." rowspan="1" colspan="1">48</td><td align="char" char="." rowspan="1" colspan="1">20594</td><td align="char" char=" " rowspan="1" colspan="1">0.69 (0.62, 0.75)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Na&#x000ef;ve and experienced</td><td align="char" rowspan="1" colspan="1">2<xref ref-type="fn" rid="jia225066-note-0018">c</xref>
</td><td align="char" char="." rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Instrument to measure adherence</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Self&#x02010;report</td><td align="char" char="." rowspan="1" colspan="1">49</td><td align="char" char="." rowspan="1" colspan="1">21974</td><td align="char" char=" " rowspan="1" colspan="1">0.71 (0.64, 0.77)</td><td align="char" char="." rowspan="1" colspan="1">0.02</td><td align="char" char="." rowspan="1" colspan="1">99</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">MEMS</td><td align="char" rowspan="1" colspan="1">2<xref ref-type="fn" rid="jia225066-note-0018">c</xref>
</td><td align="char" char="." rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Self&#x02010;report+Withdrawal<xref ref-type="fn" rid="jia225066-note-0019">d</xref>
</td><td align="char" rowspan="1" colspan="1">1<xref ref-type="fn" rid="jia225066-note-0018">c</xref>
</td><td align="char" char="." rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Self&#x02010;report+Pill Count<xref ref-type="fn" rid="jia225066-note-0020">e</xref>
</td><td align="char" rowspan="1" colspan="1">1<xref ref-type="fn" rid="jia225066-note-0018">c</xref>
</td><td align="char" char="." rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="left" rowspan="1" colspan="1"/><td align="char" char="." rowspan="1" colspan="1"/></tr><tr><td align="left" colspan="6" rowspan="1">Adherence threshold</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">&#x0003c;94%</td><td align="char" char="." rowspan="1" colspan="1">10</td><td align="char" char="." rowspan="1" colspan="1">1897</td><td align="char" char=" " rowspan="1" colspan="1">0.72 (0.51, 0.86)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">95%</td><td align="char" char="." rowspan="1" colspan="1">18</td><td align="char" char="." rowspan="1" colspan="1">7777</td><td align="char" char=" " rowspan="1" colspan="1">0.77 (0.66, 0.85)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">97</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">100%</td><td align="char" char="." rowspan="1" colspan="1">11</td><td align="char" char="." rowspan="1" colspan="1">5966</td><td align="char" char=" " rowspan="1" colspan="1">0.75 (0.62, 0.84)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Not reported</td><td align="char" char="." rowspan="1" colspan="1">14</td><td align="char" char="." rowspan="1" colspan="1">6963</td><td align="char" char=" " rowspan="1" colspan="1">0.53 (0.40, 0.66)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">99</td></tr><tr><td align="left" colspan="6" rowspan="1">Statistical models evaluating factors associated with adherence</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">Yes</td><td align="char" char="." rowspan="1" colspan="1">24</td><td align="char" char="." rowspan="1" colspan="1">11425</td><td align="char" char=" " rowspan="1" colspan="1">0.70 (0.60, 0.78)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">98</td></tr><tr><td align="left" style="padding-left:10%" rowspan="1" colspan="1">No</td><td align="char" char="." rowspan="1" colspan="1">29</td><td align="char" char="." rowspan="1" colspan="1">11178</td><td align="char" char=" " rowspan="1" colspan="1">0.70 (0.60, 0.79)</td><td align="char" char="." rowspan="1" colspan="1">&#x0003c;0.01</td><td align="char" char="." rowspan="1" colspan="1">99</td></tr></tbody></table><table-wrap-foot><fn id="jia225066-note-0015"><p>CA, Central America countries; CI, confidence interval; DR, Dominican Republic; GNI, Gross National Income; HDI, United Nations human development index; MEMS, medication event monitoring system; NA, not applicable to SA or CA; RCT, randomized clinical trials; SA, South American countries.</p></fn><fn id="jia225066-note-0016"><label>a</label><p>Study countries were categorized according to the income group, as defined by the World Bank for 2017 <xref rid="jia225066-bib-0022" ref-type="ref">22</xref>.</p></fn><fn id="jia225066-note-0017"><label>b</label><p>Study countries were categorized according to the United Nations Human Development Index (HDI) ranking and the Gross National Income (GNI) per capita (based on purchasing power parity in constant 2011 international dollars), as defined by the United Nations Development Programme <xref rid="jia225066-bib-0003" ref-type="ref">3</xref>. When a study involved multiple countries, the lower HDI or GNI value was considered.</p></fn><fn id="jia225066-note-0018"><label>c</label><p>When the number of studies in each group was &#x02264;2, meta&#x02010;analysis was not performed.</p></fn><fn id="jia225066-note-0019"><label>d</label><p>Used two methods to measure adherence, self&#x02010;report or medication withdrawal, to calculate study proportion of participants in optimal adherence.</p></fn><fn id="jia225066-note-0020"><label>e</label><p>Used two methods to measure adherence, self&#x02010;report and pill count, to calculate study proportion of participants in optimal adherence.</p></fn><fn id="jia225066-note-0021"><label>f</label><p>
<italic>p</italic>&#x02010;value for the Q statistic hypothesis test of whether there is heterogeneity, a <italic>p</italic>&#x02010;value &#x0003c;0.05 implies a rejection of the null hypothesis that the studies are homogeneous.</p></fn></table-wrap-foot><permissions><copyright-holder>John Wiley &#x00026; Sons, Ltd</copyright-holder></permissions></table-wrap></sec></sec><sec id="jia225066-sec-0020"><label>4</label><title>Discussion</title><p>This is the first systematic review and meta&#x02010;analysis that estimates a pooled proportion of adherence to ART in LAC, uniting evidence from 53 studies, 22,603 participants, in 25 countries. Results suggest that overall, 70% (95% CI: 63<bold>&#x02013;</bold>76) of PLHIV in LAC were adherent to ART and, consequently, that 30% of PLHIV in LAC may be at risk of developing AIDS&#x02010;related illnesses and transmitting the virus to others because they cannot achieve sufficient adherence to ART as required for successful viral load suppression. Mills et&#x000a0;al. (2006) <xref rid="jia225066-bib-0087" ref-type="ref">87</xref>, in a meta&#x02010;analysis of adherence to ART in sub&#x02010;Saharan Africa (27 studies; 12,116 participants) and Mhaskar et&#x000a0;al. (2013) in a meta&#x02010;analysis of adherence to ART in India (8 studies; 1666 participants)<xref rid="jia225066-bib-0088" ref-type="ref">88</xref>, found similar estimates for other low/middle income regions (77%; 95% CI: 68&#x02013;85; <italic>I</italic>
<sup><italic>2</italic></sup>
<bold>&#x000a0;=&#x000a0;</bold>98.4% and 70%; 95% CI: 59&#x02013;81, <italic>I</italic>
<sup>2</sup>
<bold>&#x000a0;=&#x000a0;</bold>96.3% respectively) than that found by our study. Pooled proportion of adherence has also been estimated by other researchers for North America (55%)<xref rid="jia225066-bib-0087" ref-type="ref">87</xref>; Spain (55%)<xref rid="jia225066-bib-0089" ref-type="ref">89</xref>; worldwide (62%)<xref rid="jia225066-bib-0090" ref-type="ref">90</xref>; and for high&#x02010;risk subgroups living with HIV such as drug users (60%)<xref rid="jia225066-bib-0091" ref-type="ref">91</xref>, pregnant women (73.5%)<xref rid="jia225066-bib-0092" ref-type="ref">92</xref>; female sex workers (76%) <xref rid="jia225066-bib-0093" ref-type="ref">93</xref>, adolescents (62%) <xref rid="jia225066-bib-0020" ref-type="ref">20</xref>, prisoners (54.6%) <xref rid="jia225066-bib-0094" ref-type="ref">94</xref> and different high&#x02010;risk populations living with HIV in China (77.61%) <xref rid="jia225066-bib-0095" ref-type="ref">95</xref>.</p><p>Our results show that, when assessing adherence, depending on the time&#x02010;frame for recall, different results might be achieved. Our results point to higher adherence (80%) in the shortest time frame and lower adherence (55%) in the longer time&#x02010;frame. These findings are consistent with the meta&#x02010;analysis of adherence among HIV&#x02010;positive drug users, conducted by Malta et&#x000a0;al. (2010) <xref rid="jia225066-bib-0091" ref-type="ref">91</xref>, where the pooled estimate for the shortest period was higher (71%) than the pooled estimated for the intermediate period (54%). Moreover, and again, similarly to Malta et&#x000a0;al. (2010) <xref rid="jia225066-bib-0091" ref-type="ref">91</xref>, the shortest time frame also yielded a less heterogeneous estimate of adherence. Taken together, these findings suggest that a shorter time frame might yield estimates that are less prone to recall bias and thus more accurate. Conversely, a longer time interval increases the chances of adherence issues, what may not be observed using a shorter time frame. That said, which adherence time frame best predicts virological failure is less known, with a few studies suggesting that the impact of the time frame might be minimal <xref rid="jia225066-bib-0021" ref-type="ref">21</xref>, <xref rid="jia225066-bib-0096" ref-type="ref">96</xref>.</p><p>There were no significant differences in the pooled adherence among different optimal adherence thresholds (&#x0003c;94%, 95%, 100%), which was similar to the findings of Ortego et&#x000a0;al. (2011) <xref rid="jia225066-bib-0090" ref-type="ref">90</xref>. Moreover, in a recent meta&#x02010;analysis conducted by Bezabhe et&#x000a0;al. (2016)<xref rid="jia225066-bib-0021" ref-type="ref">21</xref>, there were no significant differences in the pooled odds ratios for virological failure among different optimal adherence thresholds (OR <sub>&#x02265;98&#x02013;100%</sub>
<bold>&#x000a0;=&#x000a0;</bold>0.54, 95% CI: 0.29&#x02013;1.00, <italic>I</italic>
<sup>2</sup>= 85%; OR <sub>&#x02265;95%</sub>
<bold>&#x000a0;=&#x000a0;</bold>0.34, 95% CI: 0.24&#x02013;0.47, <italic>I</italic>
<sup>2</sup>
<bold>&#x000a0;=&#x000a0;</bold>92; OR <sub>&#x02265;80&#x02013;90%</sub>
<bold>&#x000a0;=&#x000a0;</bold>0.34, 95% CI: 0.23&#x02013;0.51, <italic>I</italic>
<sup>2</sup>= 0%) showing that irrespective of the cutoff point, optimal adherence to ART was associated with positive clinical outcomes.</p><p>As per Marmot, health inequalities are perhaps the most damning indictments of social and economic inequalities <xref rid="jia225066-bib-0097" ref-type="ref">97</xref>. Similar social gradients in health can be observed if we stratify the population by region, country or income. Social determinants of health can greatly affect adherence to ART. The proportion of people who reported optimal adherence to ART varied according to the country's income level, HDI and GNI per capita. We found that in studies from lower income countries the pooled proportion of adherence was higher than in studies from middle income countries. HDI and GNI per capita followed the same trend. Studies in countries with a lower HDI and GNI per capita had higher proportions of adherence than studies in countries with a higher HDI and GNI per capita. These findings are consistent with previous meta&#x02010;analysis: Uthman et&#x000a0;al. (2014) <xref rid="jia225066-bib-0098" ref-type="ref">98</xref> found that the proportion of PLHIV who achieved good adherence was significantly higher in lower&#x02010;income countries (86%) compared to higher&#x02010;income countries (67.5%; <italic>p&#x000a0;</italic>&#x0003c;<italic>&#x000a0;</italic>0.05). Although our findings suggest that less developed countries can achieve the same or higher level of adherence than more developed ones, huge differences between populations and availability of healthcare may have been included in each setting (selection bias). It is possible that in lower&#x02010;income countries participation in a research study provides better health care (e.g. ideal trial conditions and adherence counselling). In higher&#x02010;income countries, where people may have access to a better public service or can afford for a private service, other factors beyond poverty can affect ART adherence (e.g. depression and substance misuse). Bezabhe et&#x000a0;al. (2016) <xref rid="jia225066-bib-0021" ref-type="ref">21</xref> when exploring the impact of adherence on virological failure found that the pooled odds ratio for virological suppression among those with optimal adherence compared to suboptimal adherence for countries with low HDI (0.50; 95% CI: 0.35&#x02013;0.72) was lower than for countries with very high&#x02010;HDI (0.23; 95% CI: 0.15&#x02013;0.33). Suggesting that although adherence may be similar or higher, the expected effect of adherence on virologic suppression is lower in low/middle income countries. A possible explanation might be the lack of consistent virological monitoring <xref rid="jia225066-bib-0099" ref-type="ref">99</xref> with patients adhering to non&#x02010;suppressive treatment.</p><p>Measures of adherence include individual self&#x02010;report, pharmacy records, pill counts, electronic measurement devices, therapeutic drug concentrations and clinical outcomes. The easiest and therefore most frequently used method is patient self&#x02010;report. Self&#x02010;report questions consider the number or frequency of doses missed/taken, or simply asks individuals to rate their adherence level, always considering a specific time period. Questionnaires frequently use a Likert&#x02010;type scale as the response format (often five&#x02010;point ordered response ranging from the most positive to the most negative response to a statement). Although individual self&#x02010;report can be inexpensive, easy to administer, and accurately identify medication&#x02010;taking behaviour <xref rid="jia225066-bib-0100" ref-type="ref">100</xref>, they may also overestimate adherence due to social desirability (i.e. respondents answer questions in a way that will be viewed favourably by clinicians) and recall biases <xref rid="jia225066-bib-0101" ref-type="ref">101</xref>. These biases may have impacted our results, because patient's self&#x02010;reported adherence was the most common method for assessing adherence in this meta&#x02010;analysis. Self&#x02010;report questionnaires, which have a reasonable predictive power, are useful for resource&#x02010;limited clinical settings. The ACTG Adherence Questionnaire was the most extensively used instrument. It is a 5&#x02010;item self&#x02010;report measure, but frequently, only the first item (four&#x02010;day recall of how many doses have been missed) is used in clinical setting. The CEAT&#x02010;VIH was the second most used self&#x02010;report instrument. The CEAT&#x02010;VIH is a short (20 items) multidimensional self&#x02010;report instrument to measure adherence, available in six languages: English, European Spanish and Latin American Spanish, European Portuguese, Brazilian Portuguese and Romanian. Although MEMS has been used as measure of choice to validate adherence measures such as patient's self&#x02010;report or pharmacy database (medication withdrawal or refill data), the cost of this device substantially impairs its widespread use. Clinical outcomes, is considered by some researchers as one of the best measures of a patient's adherence behaviour, but the use of clinical outcomes as a proxy of adherence can always be biased by the presence of any patient&#x02010; or disease&#x02010;related factor. Each adherence measurement strategy has strengths and weaknesses. The best measurement strategy for clinical practice should take in consideration the setting, the population, and most importantly have acceptable reliability and validity.</p><p>We found that the assessment of the quality of the published studies was sometimes challenging. Many studies did not report relevant methodological details about the assessment of adherence, making it difficult to judge the strength of their findings. The absence of these data may have introduced a possible bias in the results (data retrieval bias). To promote improvement in the quality of measurement of medication adherence in research Williams et&#x000a0;al. <xref rid="jia225066-bib-0102" ref-type="ref">102</xref> have proposed a set of best practices for conducting adherence measurement. For studies using self&#x02010;report, for example, it is recommended the use of an instrument and method of administration that demonstrate both concurrent and predictive validity. When using a new instrument, it needs to be validated in a pilot test. When a scale is used to measure adherence, it needs to be culturally sensitive, worded clearly, and subjects need to know how to respond to the scaling response options with little difficulty. In addition to their recommendations, and to improve also the reporting of adherence measurement, we suggest that researchers clearly identify the instrument used, whether it was validated for use in the study population, when the assessment was carried out (date), the adherence recall time frame used, the adherence definition used (i.e. no. of pills taken/prescribed or instrument score), the optimal adherence cutoffs or thresholds adopted and ART used, which can greatly affect adherence to ART. Accurate assessment of adherence behaviour is essential for treatment planning while accurate reporting of adherence studies is essential for further advancement of the subject.</p><p>Identifying specific barriers for patients and implementing appropriate interventions to overcome them is extremely necessary to improve adherence. The social support was one of the factors associated with adherence in this systematic review and meta&#x02010;analysis. Social network and social influence, can provide a powerful approach for health behaviour change <xref rid="jia225066-bib-0103" ref-type="ref">103</xref>. Alcohol use was associated with nonadherence to ART in many studies. This association has been observed previously, where alcohol abuse can be higher in PLHIV than in the general population, and may lead to medical and psychiatric complications, poor adherence and poorer treatment outcomes <xref rid="jia225066-bib-0104" ref-type="ref">104</xref>. In addition, alcohol use is associated with intravenous drug use and risky sexual behaviour, major modes of HIV transmission <xref rid="jia225066-bib-0104" ref-type="ref">104</xref>. Unemployment was another barrier to nonadherence in LAC countries. This association exists globally, and was recently estimated with a pooled odds ratio of 1.27 (95% CI: 1.04&#x02013;1.55) in a meta&#x02010;analysis carried out by Nachega et&#x000a0;al. (2015) <xref rid="jia225066-bib-0105" ref-type="ref">105</xref>. Reporting of traditional barriers to ART such as toxicity and pill burden has reduced over time since current ART regimens are simpler and better tolerated. Consequently, the primary individual barriers to adherence have changed. In a recent meta&#x02010;analysis conducted by Shubber et&#x000a0;al. (2016) <xref rid="jia225066-bib-0106" ref-type="ref">106</xref>, individual barriers most frequently reported by patients included forgetting, being away from home, and a change to daily routine. Depression, alcohol/substance misuse, stigma, feeling sick, health service&#x02010;related barriers (i.e. distance to clinic) and stock outs were less frequently reported. In this systematic review and meta&#x02010;analysis studies reported many traditional barriers, in particular those related with alcohol and substance misuse. The presence of so many traditional barriers may be indictments that regimens in use in LAC are not aligned with WHO, PAHO and other agencies efforts to optimize drug regimens. In 2012, 4% of the patients of the region, approximately 30,000 patients out of the 725,000 that receive ART, were being treated with obsolete or inappropriate ARVs <xref rid="jia225066-bib-0107" ref-type="ref">107</xref>. Also, in many countries the number of regimens in use still exceeds 15<bold>&#x02013;</bold>20 <xref rid="jia225066-bib-0108" ref-type="ref">108</xref>.</p><p>This study has important limitations worth noting. Meta&#x02010;analysis of observational studies, unlike randomized controlled trials, are prone to biases including confounding. The high risk of selection biases within included studies may be a function of their observational design. Moreover, we found high heterogeneity among the studies indicating that adherence varied significantly across studies, possibly due to different populations, different thresholds, different time frames and methods of measurement. Accordingly, random effects models were chosen as our analytical framework to better accommodate the heterogeneity since it assumes that each study was drawn from populations that differ from each other in ways that could impact the proportion of adherents. Heterogeneity was not entirely explained by subgroup analysis. A meta&#x02010;regression could help investigate the sources of the heterogeneity across studies by studying the relationship between study&#x02010;level characteristics and adherence to ART, but it was not performed in this study due to discrepancies associated with reporting of participants&#x02019; characteristics. For example, we were not able to evaluate a possible relationship between adherence and different regimens because this information was rarely available among the included studies. Another limitation is that most of the studies included in this meta&#x02010;analysis used a cross&#x02010;sectional design, making it difficult to determine causal relationships between level of adherence and other factors. Lastly, we did not include grey literature and therefore may have missed studies that were relevant to our research question during the literature search. However, the inclusion of grey literature may itself introduce biases if the studies found were not representative of all unpublished studies. Though, our results must be interpreted with caution, considering our assumptions and limitations, meta&#x02010;analyses are still the preferred methodology in providing a qualitative interpretation of the results <xref rid="jia225066-bib-0109" ref-type="ref">109</xref>.</p></sec><sec id="jia225066-sec-0021"><label>5</label><title>Conclusions</title><p>In conclusion, our study suggests that PLHIV in LAC can achieve comparable adherence levels to other populations of developing regions though it may be below the sufficient levels required for successful long&#x02010;term viral load suppression. Monitoring ART adherence is critical to provide information about possible causes of virological failure in LAC, where viral load testing is often carried out less frequently than regional guidelines recommend <xref rid="jia225066-bib-0099" ref-type="ref">99</xref>. We encourage initiatives for improving ART adherence that consider the social determinants of health inside each context, involving community&#x02010;based organizations and social participation to address the huge socio&#x02010;economic disparities and the health inequities present across and within LAC countries.</p></sec><sec id="jia225066-sec-0022"><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec id="jia225066-sec-0023"><title>Authors' contributions</title><p>All authors contributed extensively to the work presented in this paper. JMC, TST, PML conceived the study. JMC, TST and PML created and performed the literature search strategy, JMC built the data extraction file, JMC and TST performed the data extraction and PML supervised the process. PML and LEC performed the statistical analyses, and all authors interpreted the data. JMC drafted the manuscript, and all the other authors contributed substantially to the writing and revising of the manuscript. All authors have read and approved the final version of the manuscript.</p></sec><sec sec-type="supplementary-material"><title>Supporting information</title><supplementary-material content-type="local-data" id="jia225066-sup-0001"><caption><p>
<bold>Additional file 1</bold> File in format docx. PubMed search strategy for studies of adherence to antiretroviral therapy for HIV/AIDS in Latin America and the Caribbean. </p></caption><media xlink:href="JIA2-21-e25066-s001.docx"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></sec></body><back><ack id="jia225066-sec-0024"><title>Acknowledgements</title><sec id="jia225066-sec-0025"><title>Funding sources</title><p>This work was conducted during a scholarship (JMC) supported by CAPES (Brazilian Federal Agency for Support and Evaluation of Graduate Education within the Ministry of Education of Brazil) and FAPERJ (Funda&#x000e7;&#x000e3;o Carlos Chagas Filho de Amparo &#x000e0; Pesquisa do Estado do Rio de Janeiro) at the Instituto Nacional de Infectologia Evandro Chagas &#x02010; Fiocruz (Brazilian National Institute of Infectious Diseases). PML acknowledges funding from the National Council of Technological and Scientific Development and FAPERJ.</p></sec></ack><ref-list content-type="cited-references" id="jia225066-bibl-0001"><title>References</title><ref id="jia225066-bib-0001"><label>1</label><mixed-citation publication-type="miscellaneous" id="jia225066-cit-0001">
<article-title>Population of Latin America and the Caribbean</article-title>. <year>2017</year>, Worldometers [Internet]. [cited 2017 Dec 3]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.worldometers.info/world-population/latin-america-and-the-caribbean-population/">http://www.worldometers.info/world-population/latin-america-and-the-caribbean-population/</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0002"><label>2</label><mixed-citation publication-type="miscellaneous" id="jia225066-cit-0002">
<article-title>Report for selected country groups and subjects</article-title> [Internet]. [cited 2017 Dec 3]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.imf.org/external/pubs/ft/weo/2017/02/weodata/weorept.aspx?sy=2015&#x00026;ey=2022&#x00026;scsm=1&#x00026;ssd=1&#x00026;sort=country&#x00026;ds=.&#x00026;br=1&#x00026;pr1.x=44&#x00026;pr1.y=5&#x00026;c=205&#x00026;s=NGDP_RPCH%2CNGDPD%2CPPPGDP%2CNGDPRPPPPC%2CPPPPC%2CPPPSH%2CNID_NGDP%2CNGSD_NGDP&#x00026;grp=1&#x00026;a=1">http://www.imf.org/external/pubs/ft/weo/2017/02/weodata/weorept.aspx?sy=2015&#x00026;ey=2022&#x00026;scsm=1&#x00026;ssd=1&#x00026;sort=country&#x00026;ds=.&#x00026;br=1&#x00026;pr1.x=44&#x00026;pr1.y=5&#x00026;c=205&#x00026;s=NGDP_RPCH%2CNGDPD%2CPPPGDP%2CNGDPRPPPPC%2CPPPPC%2CPPPSH%2CNID_NGDP%2CNGSD_NGDP&#x00026;grp=1&#x00026;a=1</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0003"><label>3</label><mixed-citation publication-type="miscellaneous" id="jia225066-cit-0003">
<collab collab-type="authors">United Nations Development Programme</collab>
. <article-title>Human development reports</article-title> [Internet]. 2016 [cited 2017 Apr 28]. Available from: <ext-link ext-link-type="uri" xlink:href="http://hdr.undp.org/en/composite/HDI">http://hdr.undp.org/en/composite/HDI</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0004"><label>4</label><mixed-citation publication-type="journal" id="jia225066-cit-0004">
<string-name>
<surname>Palella</surname>
<given-names>FJ</given-names>
</string-name>, <string-name>
<surname>Delaney</surname>
<given-names>KM</given-names>
</string-name>, <string-name>
<surname>Moorman</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Loveless</surname>
<given-names>MO</given-names>
</string-name>, <string-name>
<surname>Fuhrer</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Satten</surname>
<given-names>GA</given-names>
</string-name>, et&#x000a0;al. <article-title>Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection</article-title>. <source>N Engl J Med</source>. <year>1998</year>;<volume>338</volume>(<issue>13</issue>):<fpage>853</fpage>&#x02013;<lpage>60</lpage>.<pub-id pub-id-type="pmid">9516219</pub-id></mixed-citation></ref><ref id="jia225066-bib-0005"><label>5</label><mixed-citation publication-type="miscellaneous" id="jia225066-cit-0005">
<collab collab-type="authors">UNAIDS</collab>
, <collab collab-type="authors">AIDSinfo</collab>
. <article-title>Indicators</article-title> [Internet]. [cited 2017 Jul 27]. Available from: <ext-link ext-link-type="uri" xlink:href="http://aidsinfo.unaids.org/">http://aidsinfo.unaids.org/</ext-link>#</mixed-citation></ref><ref id="jia225066-bib-0006"><label>6</label><mixed-citation publication-type="journal" id="jia225066-cit-0006">
<string-name>
<surname>Rebeiro</surname>
<given-names>PF</given-names>
</string-name>, <string-name>
<surname>Cesar</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Shepherd</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>De Boni</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Cort&#x000e9;s</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Rodriguez</surname>
<given-names>F</given-names>
</string-name>, et&#x000a0;al. <article-title>Assessing the HIV Care Continuum in Latin America: progress in clinical retention, cART use and viral suppression</article-title>. <source>J Int AIDS Soc</source> [Internet]. <year>2016</year> Apr 8 [cited 2017 Aug 7];<volume>19</volume>(<issue>1</issue>). Available from: <ext-link ext-link-type="uri" xlink:href="http://www.jiasociety.org/index.php/jias/article/view/20636">http://www.jiasociety.org/index.php/jias/article/view/20636</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0007"><label>7</label><mixed-citation publication-type="miscellaneous" id="jia225066-cit-0007">
<collab collab-type="authors">Joint United Nations Programme on HIV/AIDS (UNAIDS)</collab>
. <article-title>Global aids update &#x02010; 2017</article-title>. Ending AIDS. Progress towards the 90&#x02013;90&#x02013;90 targets. <year>2017</year>.</mixed-citation></ref><ref id="jia225066-bib-0008"><label>8</label><mixed-citation publication-type="miscellaneous" id="jia225066-cit-0008">
<collab collab-type="authors">United Nations</collab>
. <article-title>Political declaration on HIV and AIDS: on the fast&#x02010;track to accelerate the fight against HIV and to end the AIDS epidemic by 2030</article-title>. General Assembly. Seventieth session. Agenda item 11. Resolution A/RES/70/266 Jun 22, 2016.</mixed-citation></ref><ref id="jia225066-bib-0009"><label>9</label><mixed-citation publication-type="journal" id="jia225066-cit-0009">
<string-name>
<surname>Paterson</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Swindells</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Mohr</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Brester</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Vergis</surname>
<given-names>EN</given-names>
</string-name>, <string-name>
<surname>Squier</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Adherence to protease inhibitor therapy and outcomes in patients with HIV infection</article-title>. <source>Ann Intern Med</source>. <year>2000</year>;<volume>133</volume>(<issue>1</issue>):<fpage>21</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">10877736</pub-id></mixed-citation></ref><ref id="jia225066-bib-0010"><label>10</label><mixed-citation publication-type="journal" id="jia225066-cit-0010">
<string-name>
<surname>Arnsten</surname>
<given-names>JH</given-names>
</string-name>, <string-name>
<surname>Demas</surname>
<given-names>PA</given-names>
</string-name>, <string-name>
<surname>Farzadegan</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Grant</surname>
<given-names>RW</given-names>
</string-name>, <string-name>
<surname>Gourevitch</surname>
<given-names>MN</given-names>
</string-name>, <string-name>
<surname>Chang</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Antiretroviral therapy adherence and viral suppression in HIV&#x02010;infected drug users: comparison of self&#x02010;report and electronic monitoring</article-title>. <source>Clin Infect Dis</source>. <year>2001</year>;<volume>33</volume>(<issue>8</issue>):<fpage>1417</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">11550118</pub-id></mixed-citation></ref><ref id="jia225066-bib-0011"><label>11</label><mixed-citation publication-type="journal" id="jia225066-cit-0011">
<string-name>
<surname>Cohen</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Chen</surname>
<given-names>YQ</given-names>
</string-name>, <string-name>
<surname>McCauley</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gamble</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Hosseinipour</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Kumarasamy</surname>
<given-names>N</given-names>
</string-name>, et&#x000a0;al. <article-title>Prevention of HIV&#x02010;1 infection with early antiretroviral therapy</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>6</issue>):<fpage>493</fpage>&#x02013;<lpage>505</lpage>.<pub-id pub-id-type="pmid">21767103</pub-id></mixed-citation></ref><ref id="jia225066-bib-0012"><label>12</label><mixed-citation publication-type="journal" id="jia225066-cit-0012">
<string-name>
<surname>Maggiolo</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Ravasio</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Ripamonti</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gregis</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Quinzan</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Arici</surname>
<given-names>C</given-names>
</string-name>, et&#x000a0;al. <article-title>Similar adherence rates favor different virologic outcomes for patients treated with nonnucleoside analogues or protease inhibitors</article-title>. <source>Clin Infect Dis</source>. <year>2005</year>;<volume>40</volume>(<issue>1</issue>):<fpage>158</fpage>&#x02013;<lpage>63</lpage>.<pub-id pub-id-type="pmid">15614706</pub-id></mixed-citation></ref><ref id="jia225066-bib-0013"><label>13</label><mixed-citation publication-type="journal" id="jia225066-cit-0013">
<string-name>
<surname>Bangsberg</surname>
<given-names>DR</given-names>
</string-name>. <article-title>Less than 95% adherence to nonnucleoside reverse&#x02010;transcriptase inhibitor therapy can lead to viral suppression</article-title>. <source>Clin Infect Dis</source>. <year>2006</year>;<volume>43</volume>(<issue>7</issue>):<fpage>939</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">16941380</pub-id></mixed-citation></ref><ref id="jia225066-bib-0014"><label>14</label><mixed-citation publication-type="journal" id="jia225066-cit-0014">
<string-name>
<surname>Shuter</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sarlo</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Kanmaz</surname>
<given-names>TJ</given-names>
</string-name>, <string-name>
<surname>Rode</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Zingman</surname>
<given-names>BS</given-names>
</string-name>. <article-title>HIV&#x02010;infected patients receiving lopinavir/ritonavir&#x02010;based antiretroviral therapy achieve high rates of virologic suppression despite adherence rates less than 95%</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2007</year>;<volume>45</volume>(<issue>1</issue>):<fpage>4</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">17460469</pub-id></mixed-citation></ref><ref id="jia225066-bib-0015"><label>15</label><mixed-citation publication-type="journal" id="jia225066-cit-0015">
<string-name>
<surname>Kobin</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Sheth</surname>
<given-names>NU</given-names>
</string-name>. <article-title>Levels of adherence required for virologic suppression among newer antiretroviral medications</article-title>. <source>Ann Pharmacother</source>. <year>2011</year>;<volume>45</volume>(<issue>3</issue>):<fpage>372</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21386024</pub-id></mixed-citation></ref><ref id="jia225066-bib-0016"><label>16</label><mixed-citation publication-type="journal" id="jia225066-cit-0016">
<string-name>
<surname>Viswanathan</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Justice</surname>
<given-names>AC</given-names>
</string-name>, <string-name>
<surname>Alexander</surname>
<given-names>GC</given-names>
</string-name>, <string-name>
<surname>Brown</surname>
<given-names>TT</given-names>
</string-name>, <string-name>
<surname>Gandhi</surname>
<given-names>NR</given-names>
</string-name>, <string-name>
<surname>McNicholl</surname>
<given-names>IR</given-names>
</string-name>, et&#x000a0;al. <article-title>Adherence and HIV RNA suppression in the current era of highly active antiretroviral therapy</article-title>. <source>JAIDS J Acquir Immune Defic Syndr</source>. <year>2015</year>;<volume>69</volume>(<issue>4</issue>):<fpage>493</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25886923</pub-id></mixed-citation></ref><ref id="jia225066-bib-0017"><label>17</label><mixed-citation publication-type="miscellaneous" id="jia225066-cit-0017">
<collab collab-type="authors">World Health Organization</collab>
. <article-title>Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach</article-title>. [Internet]. <year>2016</year> [cited 2017 Jan 28]. Available from: <ext-link ext-link-type="uri" xlink:href="http://www.ncbi.nlm.nih.gov/books/NBK374294/">http://www.ncbi.nlm.nih.gov/books/NBK374294/</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0018"><label>18</label><mixed-citation publication-type="journal" id="jia225066-cit-0018">
<string-name>
<surname>Moher</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Liberati</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Tetzlaff</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Altman</surname>
<given-names>DG</given-names>
</string-name>. <article-title>Preferred reporting items for systematic reviews and meta&#x02010;analyses: the PRISMA statement</article-title>. <source>Ann Intern Med</source>. <year>2009</year>;<volume>151</volume>(<issue>4</issue>):<fpage>264</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">19622511</pub-id></mixed-citation></ref><ref id="jia225066-bib-0019"><label>19</label><mixed-citation publication-type="miscellaneous" id="jia225066-cit-0019">
<string-name>
<surname>Costa</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Torres</surname>
<given-names>T</given-names>
</string-name>, <string-name>
<surname>Coelho</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Luz</surname>
<given-names>P</given-names>
</string-name>. <article-title>Adherence to antiretroviral therapy for HIV/aids in Latin America and the Caribbean: a systematic review and meta&#x02010;analysis</article-title>. PROSPERO 2017:CRD42017055963 [Internet]. <year>2017</year> Available from: <ext-link ext-link-type="uri" xlink:href="http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CRD42017055963">http://www.crd.york.ac.uk/PROSPERO_REBRANDING/display_record.asp?ID=CRD42017055963</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0020"><label>20</label><mixed-citation publication-type="journal" id="jia225066-cit-0020">
<string-name>
<surname>Kim</surname>
<given-names>S&#x02010;H</given-names>
</string-name>, <string-name>
<surname>Gerver</surname>
<given-names>SM</given-names>
</string-name>, <string-name>
<surname>Fidler</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Ward</surname>
<given-names>H</given-names>
</string-name>. <article-title>Adherence to antiretroviral therapy in adolescents living with HIV: systematic review and meta&#x02010;analysis</article-title>. <source>AIDS</source>. <year>2014</year>;<volume>28</volume>(<issue>13</issue>):<fpage>1945</fpage>&#x02013;<lpage>56</lpage>.<pub-id pub-id-type="pmid">24845154</pub-id></mixed-citation></ref><ref id="jia225066-bib-0021"><label>21</label><mixed-citation publication-type="journal" id="jia225066-cit-0021">
<string-name>
<surname>Bezabhe</surname>
<given-names>WM</given-names>
</string-name>, <string-name>
<surname>Chalmers</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Bereznicki</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Peterson</surname>
<given-names>GM</given-names>
</string-name>. <article-title>Adherence to antiretroviral therapy and virologic failure: a meta&#x02010;analysis</article-title>. <source>Medicine (Baltimore)</source>. <year>2016</year>;<volume>95</volume>(<issue>15</issue>):<fpage>e3361</fpage>.<pub-id pub-id-type="pmid">27082595</pub-id></mixed-citation></ref><ref id="jia225066-bib-0022"><label>22</label><mixed-citation publication-type="miscellaneous" id="jia225066-cit-0022">
<collab collab-type="authors">World Bank</collab>
. <article-title>List of economies</article-title> [Internet]. <year>2017</year> [cited 2017 Apr 4]. Available from: <ext-link ext-link-type="uri" xlink:href="http://databank.worldbank.org/data/download/site/content/CLASS.xls">databank.worldbank.org/data/download/site/content/CLASS.xls</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0023"><label>23</label><mixed-citation publication-type="journal" id="jia225066-cit-0023">
<string-name>
<surname>Kim</surname>
<given-names>SY</given-names>
</string-name>, <string-name>
<surname>Park</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Lee</surname>
<given-names>YJ</given-names>
</string-name>, <string-name>
<surname>Seo</surname>
<given-names>H&#x02010;J</given-names>
</string-name>, <string-name>
<surname>Sheen</surname>
<given-names>S&#x02010;S</given-names>
</string-name>, <string-name>
<surname>Hahn</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Testing a tool for assessing the risk of bias for nonrandomized studies showed moderate reliability and promising validity</article-title>. <source>J Clin Epidemiol</source>. <year>2013</year>;<volume>66</volume>(<issue>4</issue>):<fpage>408</fpage>&#x02013;<lpage>14</lpage>.<pub-id pub-id-type="pmid">23337781</pub-id></mixed-citation></ref><ref id="jia225066-bib-0024"><label>24</label><mixed-citation publication-type="book" id="jia225066-cit-0024">
<string-name>
<surname>Higgins</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Green</surname>
<given-names>S</given-names>
</string-name>, editors. <source>Cochrane handbook for systematic reviews of interventions version 5.1.0</source> [updated March 2011] [Internet]. <publisher-name>The Cochrane Collaboration</publisher-name>; <year>2011</year> Available from: <ext-link ext-link-type="uri" xlink:href="http://www.handbook.cochrane.org">www.handbook.cochrane.org</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0025"><label>25</label><mixed-citation publication-type="journal" id="jia225066-cit-0025">
<string-name>
<surname>DerSimonian</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Laird</surname>
<given-names>N</given-names>
</string-name>. <article-title>Meta&#x02010;analysis in clinical trials</article-title>. <source>Control Clin Trials</source>. <year>1986</year>;<volume>7</volume>(<issue>3</issue>):<fpage>177</fpage>&#x02013;<lpage>88</lpage>.<pub-id pub-id-type="pmid">3802833</pub-id></mixed-citation></ref><ref id="jia225066-bib-0026"><label>26</label><mixed-citation publication-type="journal" id="jia225066-cit-0026">
<string-name>
<surname>Higgins</surname>
<given-names>JPT</given-names>
</string-name>, <string-name>
<surname>Thompson</surname>
<given-names>SG</given-names>
</string-name>. <article-title>Quantifying heterogeneity in a meta&#x02010;analysis</article-title>. <source>Stat Med</source>. <year>2002</year>;<volume>21</volume>(<issue>11</issue>):<fpage>1539</fpage>&#x02013;<lpage>58</lpage>.<pub-id pub-id-type="pmid">12111919</pub-id></mixed-citation></ref><ref id="jia225066-bib-0027"><label>27</label><mixed-citation publication-type="journal" id="jia225066-cit-0027">
<string-name>
<surname>Bonolo</surname>
<given-names>PF</given-names>
</string-name>, <string-name>
<surname>C&#x000e9;sar</surname>
<given-names>CC</given-names>
</string-name>, <string-name>
<surname>Acurcio</surname>
<given-names>FA</given-names>
</string-name>, <string-name>
<surname>Ceccato</surname>
<given-names>MGB</given-names>
</string-name>, <string-name>
<surname>Padua</surname>
<given-names>CAM</given-names>
</string-name>, <string-name>
<surname>Alvares</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Non&#x02010;adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil</article-title>. <source>AIDS</source>. <year>2005</year>;<volume>19</volume>(<issue>Suppl 4</issue>):<fpage>S5</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">16249654</pub-id></mixed-citation></ref><ref id="jia225066-bib-0028"><label>28</label><mixed-citation publication-type="journal" id="jia225066-cit-0028">
<string-name>
<surname>Santos</surname>
<given-names>CP</given-names>
</string-name>, <string-name>
<surname>Felipe</surname>
<given-names>YX</given-names>
</string-name>, <string-name>
<surname>Braga</surname>
<given-names>PE</given-names>
</string-name>, <string-name>
<surname>Ramos</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Lima</surname>
<given-names>RO</given-names>
</string-name>, <string-name>
<surname>Segurado</surname>
<given-names>AC</given-names>
</string-name>. <article-title>Self&#x02010;perception of body changes in persons living with HIV/AIDS: prevalence and associated factors</article-title>. <source>AIDS</source>. <year>2005</year>;<volume>19</volume>(<issue>Suppl 4</issue>):<fpage>S14</fpage>&#x02013;<lpage>21</lpage>.<pub-id pub-id-type="pmid">16249648</pub-id></mixed-citation></ref><ref id="jia225066-bib-0029"><label>29</label><mixed-citation publication-type="journal" id="jia225066-cit-0029">
<string-name>
<surname>Amico</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Toro&#x02010;Alfonso</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Fisher</surname>
<given-names>JD</given-names>
</string-name>. <article-title>An empirical test of the information, motivation and behavioral skills model of antiretroviral therapy adherence</article-title>. <source>AIDS Care</source>. <year>2005</year>;<volume>17</volume>(<issue>6</issue>):<fpage>661</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">16036253</pub-id></mixed-citation></ref><ref id="jia225066-bib-0030"><label>30</label><mixed-citation publication-type="journal" id="jia225066-cit-0030">
<string-name>
<surname>Garcia</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Badaro</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Netto</surname>
<given-names>EM</given-names>
</string-name>, <string-name>
<surname>Silva</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Amorin</surname>
<given-names>FS</given-names>
</string-name>, <string-name>
<surname>Ramos</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Cross&#x02010;sectional study to evaluate factors associated with adherence to antiretroviral therapy by Brazilian HIV&#x02010;infected patients</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2006</year>;<volume>22</volume>(<issue>12</issue>):<fpage>1248</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">17209767</pub-id></mixed-citation></ref><ref id="jia225066-bib-0031"><label>31</label><mixed-citation publication-type="journal" id="jia225066-cit-0031">
<string-name>
<surname>Remien</surname>
<given-names>RH</given-names>
</string-name>, <string-name>
<surname>Bastos</surname>
<given-names>FI</given-names>
</string-name>, <string-name>
<surname>Jnr</surname>
<given-names>VT</given-names>
</string-name>, <string-name>
<surname>Raxach</surname>
<given-names>JC</given-names>
</string-name>, <string-name>
<surname>Pinto</surname>
<given-names>RM</given-names>
</string-name>, <string-name>
<surname>Parker</surname>
<given-names>RG</given-names>
</string-name>, et&#x000a0;al. <article-title>Adherence to antiretroviral therapy in a context of universal access, in Rio de Janeiro, Brazil</article-title>. <source>AIDS Care</source>. <year>2007</year>;<volume>19</volume>(<issue>6</issue>):<fpage>740</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">17573593</pub-id></mixed-citation></ref><ref id="jia225066-bib-0032"><label>32</label><mixed-citation publication-type="journal" id="jia225066-cit-0032">
<string-name>
<surname>Carvalho</surname>
<given-names>CV</given-names>
</string-name>, <string-name>
<surname>Merchan&#x02010;Hamann</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Matsushita</surname>
<given-names>R</given-names>
</string-name>. <article-title>Determinants of antiretroviral treatment adherence in Brasilia, Federal District: a case&#x02010;control study</article-title>. <source>Rev Soc Bras Med Trop</source>. <year>2007</year>;<volume>40</volume>(<issue>5</issue>):<fpage>555</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">17992413</pub-id></mixed-citation></ref><ref id="jia225066-bib-0033"><label>33</label><mixed-citation publication-type="journal" id="jia225066-cit-0033">
<string-name>
<surname>Mascolini</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Zuniga</surname>
<given-names>J</given-names>
</string-name>. <article-title>Perceptions of health, HIV disease, and HIV treatment by patients in 6 regions: analysis of the 2555&#x02010;person AIDS treatment for life international survey</article-title>. <source>J Int Assoc Physicians AIDS Care Chic</source>. <year>2008</year>;<volume>7</volume>(<issue>4</issue>):<fpage>160</fpage>&#x02013;<lpage>77</lpage>.<pub-id pub-id-type="pmid">18626118</pub-id></mixed-citation></ref><ref id="jia225066-bib-0034"><label>34</label><mixed-citation publication-type="journal" id="jia225066-cit-0034">
<string-name>
<surname>Pi&#x000f1;a Lopez</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Davila Tapia</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Jose Sanchez&#x02010;Sosa</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Togawa</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cazares Robles</surname>
<given-names>O</given-names>
</string-name>. <article-title>Association between stress and depression levels and treatment adherence among HIV&#x02010;positive individuals in Hermosillo, Mexico</article-title>. <source>Rev Panam Salud Publica</source>. <year>2008</year>;<volume>23</volume>(<issue>6</issue>):<fpage>377</fpage>&#x02013;<lpage>83</lpage>.<pub-id pub-id-type="pmid">18644205</pub-id></mixed-citation></ref><ref id="jia225066-bib-0035"><label>35</label><mixed-citation publication-type="journal" id="jia225066-cit-0035">
<string-name>
<surname>Sep&#x000fa;lveda Carrillo</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Z&#x000fa;&#x000f1;iga</surname>
<given-names>&#x000c1;M</given-names>
</string-name>, <string-name>
<surname>Amaya</surname>
<given-names>GA</given-names>
</string-name>, <string-name>
<surname>Ar&#x000e9;valo</surname>
<given-names>WL</given-names>
</string-name>, <string-name>
<surname>Arias</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Carrillo</surname>
<given-names>PA</given-names>
</string-name>, et&#x000a0;al. <article-title>Caracter&#x000ed;sticas sociodemogr&#x000e1;ficas y determinantes de adhesi&#x000f3;n terap&#x000e9;utica antirretrovial en pacientes con VIH/SIDA en dos instituciones de Bogot&#x000e1;</article-title>. <source>Rev Colomb Enferm</source> [Internet]. <year>2009</year>;<volume>4</volume>(<issue>4</issue>). Available from: <ext-link ext-link-type="uri" xlink:href="http://www.uelbosque.edu.co/sites/default/files/publicaciones/revistas/revista_colombiana_enfermeria/volumen4/caracteristicas_sociodemograficas_determinantes_adhesion_terapeutica_antirretroviral_pacientes_vih_sida.pdf">http://www.uelbosque.edu.co/sites/default/files/publicaciones/revistas/revista_colombiana_enfermeria/volumen4/caracteristicas_sociodemograficas_determinantes_adhesion_terapeutica_antirretroviral_pacientes_vih_sida.pdf</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0036"><label>36</label><mixed-citation publication-type="journal" id="jia225066-cit-0036">
<string-name>
<surname>Arrivillaga</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Ross</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Useche</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Lucia Alzate</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Correa</surname>
<given-names>D</given-names>
</string-name>. <article-title>Social position, gender role, and treatment adherence among Colombian women living with HIV/AIDS: social determinants of health approach</article-title>. <source>Rev Panam Salud Publica</source>. <year>2009</year>;<volume>26</volume>(<issue>6</issue>):<fpage>502</fpage>&#x02013;<lpage>10</lpage>.<pub-id pub-id-type="pmid">20107704</pub-id></mixed-citation></ref><ref id="jia225066-bib-0037"><label>37</label><mixed-citation publication-type="journal" id="jia225066-cit-0037">
<string-name>
<surname>Campbell</surname>
<given-names>JI</given-names>
</string-name>, <string-name>
<surname>Ruano</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Samayoa</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Estrado Muy</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Arathoon</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Young</surname>
<given-names>B</given-names>
</string-name>. <article-title>Adherence to antiretroviral therapy in an urban, free&#x02010;care HIV clinic in Guatemala City, Guatemala</article-title>. <source>J Int Assoc Physicians AIDS Care Chic</source>. <year>2010</year>;<volume>9</volume>(<issue>6</issue>):<fpage>390</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">21075914</pub-id></mixed-citation></ref><ref id="jia225066-bib-0038"><label>38</label><mixed-citation publication-type="journal" id="jia225066-cit-0038">
<string-name>
<surname>Allen</surname>
<given-names>CF</given-names>
</string-name>, <string-name>
<surname>Simon</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Edwards</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Simeon</surname>
<given-names>DT</given-names>
</string-name>. <article-title>Adherence to antiretroviral therapy by people accessing services from non&#x02010;governmental HIV support organisations in three Caribbean countries</article-title>. <source>West Indian Med J</source>. <year>2011</year>;<volume>60</volume>(<issue>3</issue>):<fpage>269</fpage>&#x02013;<lpage>75</lpage>.<pub-id pub-id-type="pmid">22224337</pub-id></mixed-citation></ref><ref id="jia225066-bib-0039"><label>39</label><mixed-citation publication-type="journal" id="jia225066-cit-0039">
<string-name>
<surname>Aragon&#x000e9;s</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>S&#x000e1;nchez</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Campos</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>P&#x000e9;rez</surname>
<given-names>J</given-names>
</string-name>. <article-title>Antiretroviral therapy adherence in persons with HIV/AIDS in Cuba</article-title>. <source>MEDICC Rev</source>. <year>2011</year>;<volume>13</volume>(<issue>2</issue>):<fpage>17</fpage>&#x02013;<lpage>23</lpage>.<pub-id pub-id-type="pmid">21654587</pub-id></mixed-citation></ref><ref id="jia225066-bib-0040"><label>40</label><mixed-citation publication-type="journal" id="jia225066-cit-0040">
<string-name>
<surname>Cardona&#x02010;Arias</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pel&#x000e1;ez&#x02010;Vanegas</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>L&#x000f3;pez&#x02010;Saldarriaga</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Duque&#x02010;Molina</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Leal&#x02010;&#x000c1;lvarez</surname>
<given-names>O</given-names>
</string-name>. <article-title>Calidad de vida relacionada con la salud en adultos con VIH/sida, Medell&#x000ed;n, Colombia, 2009</article-title>. <source>Biomedica</source>. <year>2011</year>;<volume>31</volume>(<issue>4</issue>):<fpage>532</fpage>&#x02013;<lpage>44</lpage>.<pub-id pub-id-type="pmid">22674364</pub-id></mixed-citation></ref><ref id="jia225066-bib-0041"><label>41</label><mixed-citation publication-type="journal" id="jia225066-cit-0041">
<string-name>
<surname>Casotti</surname>
<given-names>JAS</given-names>
</string-name>, <string-name>
<surname>Mendes</surname>
<given-names>AAS</given-names>
</string-name>, <string-name>
<surname>Endlich</surname>
<given-names>BN</given-names>
</string-name>, <string-name>
<surname>Tartaglia</surname>
<given-names>RS</given-names>
</string-name>, <string-name>
<surname>Queiroz</surname>
<given-names>MD</given-names>
</string-name>, <string-name>
<surname>Motta</surname>
<given-names>TQR</given-names>
</string-name>. <article-title>Factors associated with adherence to HAART in patients with HIV/aids</article-title>. <source>DST J Bras Doen&#x000e7;as Sex Transm</source> [Internet]. <year>2011</year>;<volume>23</volume>(<issue>4</issue>). Available from: <ext-link ext-link-type="uri" xlink:href="http://www.dst.uff.br/revista23-4-2011/13.Factors%20associated%20with%20adherence.pdf">http://www.dst.uff.br/revista23-4-2011/13.Factors%20associated%20with%20adherence.pdf</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0042"><label>42</label><mixed-citation publication-type="journal" id="jia225066-cit-0042">
<string-name>
<surname>Harris</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Pillinger</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Fromstein</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Gomez</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Garris</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Kanetsky</surname>
<given-names>PA</given-names>
</string-name>, et&#x000a0;al. <article-title>Risk factors for medication non&#x02010;adherence in an HIV infected population in the Dominican Republic</article-title>. <source>AIDS Behav</source>. <year>2011</year>;<volume>15</volume>(<issue>7</issue>):<fpage>1410</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">20721615</pub-id></mixed-citation></ref><ref id="jia225066-bib-0043"><label>43</label><mixed-citation publication-type="journal" id="jia225066-cit-0043">
<string-name>
<surname>Ilias</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Carandina</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Marin</surname>
<given-names>MJS</given-names>
</string-name>. <article-title>Ades&#x000e3;o &#x000e0; terapia antirretroviral de portadores do v&#x000ed;rus da imunodefici&#x000ea;ncia humana atendidos em um ambulat&#x000f3;rio da cidade de Mar&#x000ed;lia, S&#x000e3;o Paulo</article-title>. <source>Rev Baiana Sa&#x000fa;de P&#x000fa;blica</source> [Internet]. <year>2011</year>;<volume>35</volume>(<issue>2</issue>). Available from: <ext-link ext-link-type="uri" xlink:href="http://files.bvs.br/upload/S/0100-0233/2011/v35n2/a2470.pdf">http://files.bvs.br/upload/S/0100-0233/2011/v35n2/a2470.pdf</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0044"><label>44</label><mixed-citation publication-type="journal" id="jia225066-cit-0044">
<string-name>
<surname>Mu&#x000f1;oz</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bayona</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sanchez</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Arevalo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sebastian</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Arteaga</surname>
<given-names>F</given-names>
</string-name>, et&#x000a0;al. <article-title>Matching social support to individual needs: a community&#x02010;based intervention to improve HIV treatment adherence in a resource&#x02010;poor setting</article-title>. <source>AIDS Behav</source>. <year>2011</year>;<volume>15</volume>(<issue>7</issue>):<fpage>1454</fpage>&#x02013;<lpage>64</lpage>.<pub-id pub-id-type="pmid">20383572</pub-id></mixed-citation></ref><ref id="jia225066-bib-0045"><label>45</label><mixed-citation publication-type="journal" id="jia225066-cit-0045">
<string-name>
<surname>Costa</surname>
<given-names>TM</given-names>
</string-name>, <string-name>
<surname>Barbosa</surname>
<given-names>BJ</given-names>
</string-name>, <string-name>
<surname>Gomes e Costa</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Sigulem</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>de F&#x000e1;tima Marin</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Filho</surname>
<given-names>AC</given-names>
</string-name>, et&#x000a0;al. <article-title>Results of a randomized controlled trial to assess the effects of a mobile SMS&#x02010;based intervention on treatment adherence in HIV/AIDS&#x02010;infected Brazilian women and impressions and satisfaction with respect to incoming messages</article-title>. <source>Int J Med Inf</source>. <year>2012</year>;<volume>81</volume>(<issue>4</issue>):<fpage>257</fpage>&#x02013;<lpage>69</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0046"><label>46</label><mixed-citation publication-type="journal" id="jia225066-cit-0046">
<string-name>
<surname>Nachega</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Morroni</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Zuniga</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Schechter</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rockstroh</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Solomon</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>HIV treatment adherence, patient health literacy, and health care provider&#x02010;patient communication: results from the 2010 AIDS Treatment for Life International Survey</article-title>. <source>J Int Assoc Physicians AIDS Care Chic</source>. <year>2012</year>;<volume>11</volume>(<issue>2</issue>):<fpage>128</fpage>&#x02013;<lpage>33</lpage>.<pub-id pub-id-type="pmid">22361449</pub-id></mixed-citation></ref><ref id="jia225066-bib-0047"><label>47</label><mixed-citation publication-type="journal" id="jia225066-cit-0047">
<string-name>
<surname>Gutierrez</surname>
<given-names>EB</given-names>
</string-name>, <string-name>
<surname>Sartori</surname>
<given-names>AMC</given-names>
</string-name>, <string-name>
<surname>Schmidt</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Piloto</surname>
<given-names>BM</given-names>
</string-name>, <string-name>
<surname>Franca</surname>
<given-names>BB</given-names>
</string-name>, <string-name>
<surname>de Oliveira</surname>
<given-names>AS</given-names>
</string-name>, et&#x000a0;al. <article-title>Measuring adherence to antiretroviral treatment: the role of pharmacy records of drug withdrawals</article-title>. <source>AIDS Behav</source>. <year>2012</year>;<volume>16</volume>(<issue>6</issue>):<fpage>1482</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">22392157</pub-id></mixed-citation></ref><ref id="jia225066-bib-0048"><label>48</label><mixed-citation publication-type="journal" id="jia225066-cit-0048">
<string-name>
<surname>Alave</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Paz</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gonz&#x000e1;lez</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Campos</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Rodr&#x000ed;guez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Willig</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Factores asociados a falla virol&#x000f3;gica en pacientes infectados con VIH que reciben terapia anti&#x02010;retroviral en un hospital p&#x000fa;blico del Per&#x000fa;</article-title>. <source>Rev Chil Infectol</source>. <year>2013</year>;<volume>30</volume>(<issue>1</issue>):<fpage>42</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0049"><label>49</label><mixed-citation publication-type="journal" id="jia225066-cit-0049">
<string-name>
<surname>Hanif</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Bastos</surname>
<given-names>FI</given-names>
</string-name>, <string-name>
<surname>Malta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bertoni</surname>
<given-names>N</given-names>
</string-name>, <string-name>
<surname>Surkan</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Winch</surname>
<given-names>PJ</given-names>
</string-name>, et&#x000a0;al. <article-title>Individual and contextual factors of influence on adherence to antiretrovirals among people attending public clinics in Rio de Janeiro, Brazil</article-title>. <source>BMC Public Health</source>. <year>2013</year>;<volume>13</volume>:<fpage>574</fpage>.<pub-id pub-id-type="pmid">23758780</pub-id></mixed-citation></ref><ref id="jia225066-bib-0050"><label>50</label><mixed-citation publication-type="journal" id="jia225066-cit-0050">
<string-name>
<surname>Malow</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>D&#x000e9;vieux</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Stein</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Rosenberg</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Jean&#x02010;Gilles</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Attonito</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Depression, substance abuse and other contextual predictors of adherence to antiretroviral therapy (ART) among Haitians</article-title>. <source>AIDS Behav</source>. <year>2013</year>;<volume>17</volume>(<issue>4</issue>):<fpage>1221</fpage>&#x02013;<lpage>30</lpage>.<pub-id pub-id-type="pmid">23338563</pub-id></mixed-citation></ref><ref id="jia225066-bib-0051"><label>51</label><mixed-citation publication-type="journal" id="jia225066-cit-0051">
<string-name>
<surname>de Padoin</surname>
<given-names>SMM</given-names>
</string-name>, <string-name>
<surname>Zuge</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>dos Santos</surname>
<given-names>&#x000c9;EP</given-names>
</string-name>, <string-name>
<surname>Primeira</surname>
<given-names>MR</given-names>
</string-name>, <string-name>
<surname>Aldrighi</surname>
<given-names>JD</given-names>
</string-name>, <string-name>
<surname>de Paula</surname>
<given-names>CC</given-names>
</string-name>. <article-title>Ades&#x000e3;o &#x000e0; terapia antirretroviral para HIV/AIDS*</article-title>. <source>Cogitare Enferm</source>. <year>2013</year>;<volume>18</volume>(<issue>3</issue>):<fpage>446</fpage>&#x02013;<lpage>51</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0052"><label>52</label><mixed-citation publication-type="journal" id="jia225066-cit-0052">
<string-name>
<surname>Teixeira</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Dourado Mde</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Santos</surname>
<given-names>MP</given-names>
</string-name>, <string-name>
<surname>Brites</surname>
<given-names>C</given-names>
</string-name>. <article-title>Impact of use of alcohol and illicit drugs by AIDS patients on adherence to antiretroviral therapy in Bahia, Brazil</article-title>. <source>AIDS Res Hum Retroviruses</source>. <year>2013</year>;<volume>29</volume>(<issue>5</issue>):<fpage>799</fpage>&#x02013;<lpage>804</lpage>.<pub-id pub-id-type="pmid">23294471</pub-id></mixed-citation></ref><ref id="jia225066-bib-0053"><label>53</label><mixed-citation publication-type="journal" id="jia225066-cit-0053">
<string-name>
<surname>Tietzmann</surname>
<given-names>DC</given-names>
</string-name>, <string-name>
<surname>B&#x000e9;ria</surname>
<given-names>JU</given-names>
</string-name>, <string-name>
<surname>dos Santos</surname>
<given-names>GM</given-names>
</string-name>, <string-name>
<surname>Mallmann</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Trombini</surname>
<given-names>ES</given-names>
</string-name>, <string-name>
<surname>Schermann</surname>
<given-names>LB</given-names>
</string-name>. <article-title>Preval&#x000ea;ncias de ades&#x000e3;o &#x000e0; terapia antirretroviral e fatores associados em pacientes adultos de tr&#x000ea;s centros urbanos do Sul do Brasil</article-title>. <source>Aletheia</source>. <year>2013</year>;<volume>41</volume>:<fpage>154</fpage>&#x02013;<lpage>63</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0054"><label>54</label><mixed-citation publication-type="journal" id="jia225066-cit-0054">
<string-name>
<surname>Varela&#x02010;Ar&#x000e9;valo</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>G&#x000f3;mez Guti&#x000e9;rrez</surname>
<given-names>OL</given-names>
</string-name>, <string-name>
<surname>Mueses Mar&#x000ed;an</surname>
<given-names>HF</given-names>
</string-name>, <string-name>
<surname>Galindo Quintero</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Tello Bol&#x000ed;var</surname>
<given-names>IC</given-names>
</string-name>. <article-title>Factores relacionados con la adherencia al tratamiento farmacol&#x000f3;gico para el VIH/SIDA</article-title>. <source>Salud Uninorte</source>. <year>2013</year>;<volume>29</volume>(<issue>1</issue>):<fpage>83</fpage>&#x02013;<lpage>95</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0055"><label>55</label><mixed-citation publication-type="journal" id="jia225066-cit-0055">
<string-name>
<surname>Basso</surname>
<given-names>CR</given-names>
</string-name>, <string-name>
<surname>Santa Helena</surname>
<given-names>ET</given-names>
</string-name>, <string-name>
<surname>Magalhaes Caraciolo</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Paiva</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Battistela Nemes</surname>
<given-names>MI</given-names>
</string-name>. <article-title>Exploring ART intake scenes in a human rights&#x02010;based intervention to improve adherence: a randomized controlled trial</article-title>. <source>AIDS Behav</source>. <year>2013</year>;<volume>17</volume>(<issue>1</issue>):<fpage>181</fpage>&#x02013;<lpage>92</lpage>.<pub-id pub-id-type="pmid">22527264</pub-id></mixed-citation></ref><ref id="jia225066-bib-0056"><label>56</label><mixed-citation publication-type="journal" id="jia225066-cit-0056">
<string-name>
<surname>Balandr&#x000e1;n</surname>
<given-names>DA</given-names>
</string-name>, <string-name>
<surname>Guti&#x000e9;rrez</surname>
<given-names>JP</given-names>
</string-name>, <string-name>
<surname>Romero</surname>
<given-names>M</given-names>
</string-name>. <article-title>Evaluaci&#x000f3;n de la adherencia antirretroviral en M&#x000e9;xico: adherencia de cuatro d&#x000ed;as vs. &#x000ed;ndice de adherencia</article-title>. <source>Rev Invest Clin</source>. <year>2013</year>;<volume>65</volume>(<issue>5</issue>):<fpage>384</fpage>&#x02013;<lpage>91</lpage>.<pub-id pub-id-type="pmid">24687337</pub-id></mixed-citation></ref><ref id="jia225066-bib-0057"><label>57</label><mixed-citation publication-type="journal" id="jia225066-cit-0057">
<string-name>
<surname>Calvetti</surname>
<given-names>P&#x000dc;</given-names>
</string-name>, <string-name>
<surname>Giovelli</surname>
<given-names>GRM</given-names>
</string-name>, <string-name>
<surname>Gauer</surname>
<given-names>GJC</given-names>
</string-name>, <string-name>
<surname>de Moraes</surname>
<given-names>JFD</given-names>
</string-name>. <article-title>Psychosocial factors associated with adherence to treatment and quality of life in people living with HIV/AIDS in Brazil</article-title>. <source>J Bras Psiquiatr</source>. <year>2014</year>;<volume>63</volume>(<issue>1</issue>):<fpage>8</fpage>&#x02013;<lpage>15</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0058"><label>58</label><mixed-citation publication-type="journal" id="jia225066-cit-0058">
<string-name>
<surname>Ivers</surname>
<given-names>LC</given-names>
</string-name>, <string-name>
<surname>Teng</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Jerome</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Bonds</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Freedberg</surname>
<given-names>KA</given-names>
</string-name>, <string-name>
<surname>Franke</surname>
<given-names>MF</given-names>
</string-name>. <article-title>A randomized trial of ready&#x02010;to&#x02010;use supplementary food versus corn&#x02010;soy blend plus as food rations for HIV&#x02010;infected adults on antiretroviral therapy in rural Haiti</article-title>. <source>Clin Infect Dis</source>. <year>2014</year>;<volume>58</volume>(<issue>8</issue>):<fpage>1176</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">24536058</pub-id></mixed-citation></ref><ref id="jia225066-bib-0059"><label>59</label><mixed-citation publication-type="journal" id="jia225066-cit-0059">
<string-name>
<surname>de Jacques</surname>
<given-names>IJAA</given-names>
</string-name>, <string-name>
<surname>de Santana</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>de Moraes</surname>
<given-names>DCA</given-names>
</string-name>, <string-name>
<surname>de Souza</surname>
<given-names>AFM</given-names>
</string-name>, <string-name>
<surname>da Abr&#x000e3;o</surname>
<given-names>FMS</given-names>
</string-name>, <string-name>
<surname>de Oliveira</surname>
<given-names>RC</given-names>
</string-name>. <article-title>Avalia&#x000e7;&#x000e3;o da Ades&#x000e3;o &#x000e0; Terapia Antirretroviralentre Pacientes em Atendimento Ambulatorial</article-title>. <source>Rev Bras Ci&#x000ea;nc Sa&#x000fa;de</source>. <year>2014</year>;<volume>18</volume>(<issue>4</issue>):<fpage>303</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0060"><label>60</label><mixed-citation publication-type="journal" id="jia225066-cit-0060">
<string-name>
<surname>Silva</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Reis</surname>
<given-names>RK</given-names>
</string-name>, <string-name>
<surname>Nogueira</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Gir</surname>
<given-names>E</given-names>
</string-name>. <article-title>Quality of life, clinical characteristics and treatment adherence of people living with HIV/AIDS</article-title>. <source>Rev Lat Am Enferm</source>. <year>2014</year>;<volume>22</volume>(<issue>6</issue>):<fpage>994</fpage>&#x02013;<lpage>1000</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0061"><label>61</label><mixed-citation publication-type="journal" id="jia225066-cit-0061">
<string-name>
<surname>Varela</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Galdames</surname>
<given-names>S</given-names>
</string-name>. <article-title>Depresi&#x000f3;n y adhesi&#x000f3;n a terapia anti&#x02010;retroviral en pacientes con infecci&#x000f3;n por VIH atendidos en el Hospital San Pablo de Coquimbo, Chile</article-title>. <source>Rev Chil Infectol</source>. <year>2014</year>;<volume>31</volume>(<issue>3</issue>):<fpage>323</fpage>&#x02013;<lpage>8</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0062"><label>62</label><mixed-citation publication-type="journal" id="jia225066-cit-0062">
<string-name>
<surname>Silveira</surname>
<given-names>MPT</given-names>
</string-name>, <string-name>
<surname>Guttier</surname>
<given-names>MC</given-names>
</string-name>, <string-name>
<surname>Page</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Moreira</surname>
<given-names>LB</given-names>
</string-name>. <article-title>Randomized controlled trial to evaluate the impact of pharmaceutical care on therapeutic success in HIV&#x02010;infected patients in Southern Brazil</article-title>. <source>AIDS Behav</source>. <year>2014</year>;<volume>18</volume>(<issue>Suppl 1</issue>):<fpage>S75</fpage>&#x02013;<lpage>84</lpage>.<pub-id pub-id-type="pmid">23975474</pub-id></mixed-citation></ref><ref id="jia225066-bib-0063"><label>63</label><mixed-citation publication-type="journal" id="jia225066-cit-0063">
<string-name>
<surname>De La Hoz</surname>
<given-names>JM</given-names>
</string-name>, <string-name>
<surname>Bolano</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Cardenas</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Gonzalez</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Sabbag</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Palacio</surname>
<given-names>L</given-names>
</string-name>, et&#x000a0;al. <article-title>Characterization of treatment failure in HIV positive patients in the Colombian Caribbean region</article-title>. <source>Colomb Medica Cali Colomb</source>. <year>2014</year>;<volume>45</volume>(<issue>4</issue>):<fpage>162</fpage>&#x02013;<lpage>7</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0064"><label>64</label><mixed-citation publication-type="journal" id="jia225066-cit-0064">
<string-name>
<surname>Ferro</surname>
<given-names>EG</given-names>
</string-name>, <string-name>
<surname>Weikum</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Vagenas</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Copenhaver</surname>
<given-names>MM</given-names>
</string-name>, <string-name>
<surname>Gonzales</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Peinado</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Alcohol use disorders negatively influence antiretroviral medication adherence among men who have sex with men in Peru</article-title>. <source>AIDS Care</source>. <year>2015</year>;<volume>27</volume>(<issue>1</issue>):<fpage>93</fpage>&#x02013;<lpage>104</lpage>.<pub-id pub-id-type="pmid">25277252</pub-id></mixed-citation></ref><ref id="jia225066-bib-0065"><label>65</label><mixed-citation publication-type="journal" id="jia225066-cit-0065">
<string-name>
<surname>Krishnan</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Ferro</surname>
<given-names>EG</given-names>
</string-name>, <string-name>
<surname>Weikum</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Vagenas</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Lama</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Sanchez</surname>
<given-names>J</given-names>
</string-name>, et&#x000a0;al. <article-title>Communication technology use and mHealth acceptance among HIV&#x02010;infected men who have sex with men in Peru: implications for HIV prevention and treatment</article-title>. <source>AIDS Care</source>. <year>2015</year>;<volume>27</volume>(<issue>3</issue>):<fpage>273</fpage>&#x02013;<lpage>82</lpage>.<pub-id pub-id-type="pmid">25285464</pub-id></mixed-citation></ref><ref id="jia225066-bib-0066"><label>66</label><mixed-citation publication-type="journal" id="jia225066-cit-0066">
<string-name>
<surname>Magidson</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Biello</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Safren</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Rosenberger</surname>
<given-names>JG</given-names>
</string-name>, <string-name>
<surname>Novak</surname>
<given-names>DS</given-names>
</string-name>, <string-name>
<surname>Mayer</surname>
<given-names>KH</given-names>
</string-name>, et&#x000a0;al. <article-title>Engagement in HIV care and sexual transmission risk behavior among men who have sex with men using online social/sexual networking in Latin America</article-title>. <source>AIDS Care</source>. <year>2015</year>;<volume>27</volume>(<issue>8</issue>):<fpage>1055</fpage>&#x02013;<lpage>62</lpage>.<pub-id pub-id-type="pmid">25738655</pub-id></mixed-citation></ref><ref id="jia225066-bib-0067"><label>67</label><mixed-citation publication-type="journal" id="jia225066-cit-0067">
<string-name>
<surname>Malbergier</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>do Amaral</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Cardoso</surname>
<given-names>LD</given-names>
</string-name>. <article-title>Alcohol dependence and CD4 cell count: is there a relationship?</article-title>
<source>AIDS Care</source>. <year>2015</year>;<volume>27</volume>(<issue>1</issue>):<fpage>54</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25179410</pub-id></mixed-citation></ref><ref id="jia225066-bib-0068"><label>68</label><mixed-citation publication-type="journal" id="jia225066-cit-0068">
<string-name>
<surname>P&#x000e9;rez&#x02010;Salgado</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Compean&#x02010;Dard&#x000f3;n</surname>
<given-names>MS</given-names>
</string-name>, <string-name>
<surname>Staines&#x02010;Orozco</surname>
<given-names>MG</given-names>
</string-name>, <string-name>
<surname>Ortiz&#x02010;Hern&#x000e1;ndez</surname>
<given-names>L</given-names>
</string-name>. <article-title>Satisfaction with healthcare services and adherence to antiretroviral therapy among patients with HIV attending two public institutions</article-title>. <source>Rev Invest Clin</source>. <year>2015</year>;<volume>67</volume>(<issue>2</issue>):<fpage>80</fpage>&#x02013;<lpage>8</lpage>.<pub-id pub-id-type="pmid">25938840</pub-id></mixed-citation></ref><ref id="jia225066-bib-0069"><label>69</label><mixed-citation publication-type="journal" id="jia225066-cit-0069">
<string-name>
<surname>Santill&#x000e1;n Torres Torija</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Villagr&#x000e1;n V&#x000e1;zquez</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Robles Montijo</surname>
<given-names>SS</given-names>
</string-name>, <string-name>
<surname>de Eguiluz Romo</surname>
<given-names>LL</given-names>
</string-name>. <article-title>The information and motivation and behavioral skills model of ART adherence among HIV&#x02010;positive adults in Mexico</article-title>. <source>J Int Assoc Provid AIDS Care</source>. <year>2015</year>;<volume>14</volume>(<issue>4</issue>):<fpage>335</fpage>&#x02013;<lpage>42</lpage>.<pub-id pub-id-type="pmid">25979257</pub-id></mixed-citation></ref><ref id="jia225066-bib-0070"><label>70</label><mixed-citation publication-type="journal" id="jia225066-cit-0070">
<string-name>
<surname>Tello&#x02010;Vel&#x000e1;squez</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>D&#x000ed;az&#x02010;Llanes</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Mezones&#x02010;Holgu&#x000ed;n</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Rodr&#x000ed;guez&#x02010;Morales</surname>
<given-names>AJ</given-names>
</string-name>, <string-name>
<surname>Huaman&#x000ed;</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Hern&#x000e1;ndez</surname>
<given-names>AV</given-names>
</string-name>, et&#x000a0;al. <article-title>La mala calidad de sue&#x000f1;o se asocia a una menor adherencia al tratamiento antirretroviral de gran actividad en pacientes peruanos con infecci&#x000f3;n por VIH/SIDA</article-title>. <source>Cad Saude Publica</source>. <year>2015</year>;<volume>31</volume>(<issue>5</issue>):<fpage>989</fpage>&#x02013;<lpage>1002</lpage>.<pub-id pub-id-type="pmid">26083174</pub-id></mixed-citation></ref><ref id="jia225066-bib-0071"><label>71</label><mixed-citation publication-type="journal" id="jia225066-cit-0071">
<string-name>
<surname>Tufano</surname>
<given-names>CS</given-names>
</string-name>, <string-name>
<surname>Amaral</surname>
<given-names>RA</given-names>
</string-name>, <string-name>
<surname>Cardoso</surname>
<given-names>LR</given-names>
</string-name>, <string-name>
<surname>Malbergier</surname>
<given-names>A</given-names>
</string-name>. <article-title>The influence of depressive symptoms and substance use on adherence to antiretroviral therapy. A cross&#x02010;sectional prevalence study</article-title>. <source>Sao Paulo Med J</source>. <year>2015</year>;<volume>133</volume>(<issue>3</issue>):<fpage>179</fpage>&#x02013;<lpage>86</lpage>.<pub-id pub-id-type="pmid">25250800</pub-id></mixed-citation></ref><ref id="jia225066-bib-0072"><label>72</label><mixed-citation publication-type="journal" id="jia225066-cit-0072">
<string-name>
<surname>Zulliger</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Barrington</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Donastorg</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Perez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Kerrigan</surname>
<given-names>D</given-names>
</string-name>. <article-title>High drop&#x02010;off along the HIV care continuum and ART Interruption among female sex workers in the Dominican Republic</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>2015</year>;<volume>69</volume>(<issue>2</issue>):<fpage>216</fpage>&#x02013;<lpage>22</lpage>.<pub-id pub-id-type="pmid">25714246</pub-id></mixed-citation></ref><ref id="jia225066-bib-0073"><label>73</label><mixed-citation publication-type="journal" id="jia225066-cit-0073">
<string-name>
<surname>Pacifico</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gutierrez</surname>
<given-names>C</given-names>
</string-name>. <article-title>Information about the medicines and adherence to high activity antiretroviral treatment in patients with HIV/AIDS in a hospital of Lima, Peru</article-title>. <source>Rev Peru Med Exp Salud Publica</source>. <year>2015</year>;<volume>32</volume>(<issue>1</issue>):<fpage>66</fpage>&#x02013;<lpage>72</lpage>.<pub-id pub-id-type="pmid">26102107</pub-id></mixed-citation></ref><ref id="jia225066-bib-0074"><label>74</label><mixed-citation publication-type="journal" id="jia225066-cit-0074">
<string-name>
<surname>Magidson</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Li</surname>
<given-names>X</given-names>
</string-name>, <string-name>
<surname>Mimiaga</surname>
<given-names>MJ</given-names>
</string-name>, <string-name>
<surname>Moore</surname>
<given-names>AT</given-names>
</string-name>, <string-name>
<surname>Srithanaviboonchai</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Friedman</surname>
<given-names>RK</given-names>
</string-name>, et&#x000a0;al. <article-title>Antiretroviral medication adherence and amplified HIV transmission risk among sexually active HIV&#x02010;infected individuals in three diverse international settings</article-title>. <source>AIDS Behav</source>. <year>2016</year>;<volume>20</volume>:<fpage>699</fpage>&#x02013;<lpage>709</lpage>.<pub-id pub-id-type="pmid">26246068</pub-id></mixed-citation></ref><ref id="jia225066-bib-0075"><label>75</label><mixed-citation publication-type="journal" id="jia225066-cit-0075">
<string-name>
<surname>Drachler</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Drachler</surname>
<given-names>CW</given-names>
</string-name>, <string-name>
<surname>Teixeira</surname>
<given-names>LB</given-names>
</string-name>, <string-name>
<surname>Leite</surname>
<given-names>JC</given-names>
</string-name>. <article-title>The scale of self&#x02010;efficacy expectations of adherence to antiretroviral treatment: a tool for identifying risk for non&#x02010;adherence to treatment for HIV</article-title>. <source>PLoS ONE</source>. <year>2016</year>;<volume>11</volume>(<issue>2</issue>):<fpage>e0147443</fpage>.<pub-id pub-id-type="pmid">26895270</pub-id></mixed-citation></ref><ref id="jia225066-bib-0076"><label>76</label><mixed-citation publication-type="journal" id="jia225066-cit-0076">
<string-name>
<surname>de Souza</surname>
<given-names>GO</given-names>
</string-name>, <string-name>
<surname>Tib&#x000fa;rcio</surname>
<given-names>AACM</given-names>
</string-name>, <string-name>
<surname>Koike</surname>
<given-names>MK</given-names>
</string-name>. <article-title>Appropriate adherence to antiretroviral therapy in the Alto Paranaiba, Minas Gerais, Brazil</article-title>. <source>Med Expr</source>. <year>2016</year>;<volume>3</volume>(<issue>3</issue>):<fpage>M160305</fpage>.</mixed-citation></ref><ref id="jia225066-bib-0077"><label>77</label><mixed-citation publication-type="journal" id="jia225066-cit-0077">
<string-name>
<surname>De Boni</surname>
<given-names>RB</given-names>
</string-name>, <string-name>
<surname>Shepherd</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Grinsztejn</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Cesar</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Cortes</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Padgett</surname>
<given-names>D</given-names>
</string-name>, et&#x000a0;al. <article-title>Substance use and adherence among people living with HIV/AIDS receiving cART in Latin America</article-title>. <source>AIDS Behav</source>. <year>2016</year>;<volume>20</volume>:<fpage>2692</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27091028</pub-id></mixed-citation></ref><ref id="jia225066-bib-0078"><label>78</label><mixed-citation publication-type="journal" id="jia225066-cit-0078">
<string-name>
<surname>Biello</surname>
<given-names>KB</given-names>
</string-name>, <string-name>
<surname>Oldenburg</surname>
<given-names>CE</given-names>
</string-name>, <string-name>
<surname>Rosenberger</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Mayer</surname>
<given-names>KH</given-names>
</string-name>, <string-name>
<surname>Novak</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Mimiaga</surname>
<given-names>MJ</given-names>
</string-name>. <article-title>Is involvement in sex work associated with engagement in HIV&#x02010;related medical care in Latin American men who have sex with men? Results of a large. Multinational Internet Survey</article-title>. <source>LGBT Health</source>. <year>2016</year>;<volume>3</volume>(<issue>3</issue>):<fpage>233</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26789395</pub-id></mixed-citation></ref><ref id="jia225066-bib-0079"><label>79</label><mixed-citation publication-type="journal" id="jia225066-cit-0079">
<string-name>
<surname>Fleming</surname>
<given-names>PJ</given-names>
</string-name>, <string-name>
<surname>Barrington</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Perez</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Donastorg</surname>
<given-names>Y</given-names>
</string-name>, <string-name>
<surname>Kerrigan</surname>
<given-names>D</given-names>
</string-name>. <article-title>HIV testing, care, and treatment experiences among the steady male partners of female sex workers living with HIV in the Dominican Republic</article-title>. <source>Aids Care&#x02010;Psychol Socio&#x02010;Med Asp AidsHiv</source>. <year>2016</year>;<volume>28</volume>(<issue>6</issue>):<fpage>699</fpage>&#x02013;<lpage>704</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0080"><label>80</label><mixed-citation publication-type="journal" id="jia225066-cit-0080">
<string-name>
<surname>Chesney</surname>
<given-names>MA</given-names>
</string-name>, <string-name>
<surname>Ickovics</surname>
<given-names>JR</given-names>
</string-name>, <string-name>
<surname>Chambers</surname>
<given-names>DB</given-names>
</string-name>, <string-name>
<surname>Gifford</surname>
<given-names>AL</given-names>
</string-name>, <string-name>
<surname>Neidig</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Zwickl</surname>
<given-names>B</given-names>
</string-name>, et&#x000a0;al. <article-title>Self&#x02010;reported adherence to antiretroviral medications among participants in HIV clinical trials: The AACTG Adherence Instruments</article-title>. <source>AIDS Care</source>. <year>2000</year>;<volume>12</volume>(<issue>3</issue>):<fpage>255</fpage>&#x02013;<lpage>66</lpage>.<pub-id pub-id-type="pmid">10928201</pub-id></mixed-citation></ref><ref id="jia225066-bib-0081"><label>81</label><mixed-citation publication-type="journal" id="jia225066-cit-0081">
<string-name>
<surname>Varela</surname>
<given-names>MT</given-names>
</string-name>, <string-name>
<surname>Salazar</surname>
<given-names>IC</given-names>
</string-name>, <string-name>
<surname>Correa</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Duarte</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Tamayo</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Salazar</surname>
<given-names>&#x000c1;E</given-names>
</string-name>. <article-title>La evaluaci&#x000f3;n integral de la adherencia al tratamiento en mujeres con VIH/SIDA: validaci&#x000f3;n de un cuestionario</article-title>. <source>Colomb M&#x000e9;dica</source>. <year>2009</year>;<volume>40</volume>(<issue>4</issue>):<fpage>387</fpage>&#x02013;<lpage>98</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0082"><label>82</label><mixed-citation publication-type="journal" id="jia225066-cit-0082">
<string-name>
<surname>Remor</surname>
<given-names>E</given-names>
</string-name>. <article-title>Systematic review of the psychometric properties of the questionnaire to evaluate the adherence to HIV therapy (CEAT&#x02010;VIH)</article-title>. <source>Patient</source>. <year>2013</year>;<volume>6</volume>(<issue>2</issue>):<fpage>61</fpage>&#x02013;<lpage>73</lpage>.<pub-id pub-id-type="pmid">23558754</pub-id></mixed-citation></ref><ref id="jia225066-bib-0083"><label>83</label><mixed-citation publication-type="journal" id="jia225066-cit-0083">
<string-name>
<surname>Morisky</surname>
<given-names>DE</given-names>
</string-name>, <string-name>
<surname>Green</surname>
<given-names>LW</given-names>
</string-name>, <string-name>
<surname>Levine</surname>
<given-names>DM</given-names>
</string-name>. <article-title>Concurrent and predictive validity of a self&#x02010;reported measure of medication adherence</article-title>. <source>Med Care</source>. <year>1986</year>;<volume>24</volume>(<issue>1</issue>):<fpage>67</fpage>&#x02013;<lpage>74</lpage>.<pub-id pub-id-type="pmid">3945130</pub-id></mixed-citation></ref><ref id="jia225066-bib-0084"><label>84</label><mixed-citation publication-type="journal" id="jia225066-cit-0084">
<string-name>
<surname>Duong</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Piroth</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Grappin</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Forte</surname>
<given-names>F</given-names>
</string-name>, <string-name>
<surname>Peytavin</surname>
<given-names>G</given-names>
</string-name>, <string-name>
<surname>Buisson</surname>
<given-names>M</given-names>
</string-name>, et&#x000a0;al. <article-title>Evaluation of the Patient Medication Adherence Questionnaire as a tool for self&#x02010;reported adherence assessment in HIV&#x02010;infected patients on antiretroviral regimens</article-title>. <source>HIV Clin Trials</source>. <year>2001</year>;<volume>2</volume>(<issue>2</issue>):<fpage>128</fpage>&#x02013;<lpage>35</lpage>.<pub-id pub-id-type="pmid">11590521</pub-id></mixed-citation></ref><ref id="jia225066-bib-0085"><label>85</label><mixed-citation publication-type="journal" id="jia225066-cit-0085">
<string-name>
<surname>Knobel</surname>
<given-names>H</given-names>
</string-name>, <string-name>
<surname>Alonso</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Casado</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Collazos</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Gonz&#x000e1;lez</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Ruiz</surname>
<given-names>I</given-names>
</string-name>, et&#x000a0;al. <article-title>Validation of a simplified medication adherence questionnaire in a large cohort of HIV&#x02010;infected patients: the GEEMA Study</article-title>. <source>AIDS</source>. <year>2002</year>;<volume>16</volume>(<issue>4</issue>):<fpage>605</fpage>&#x02013;<lpage>13</lpage>.<pub-id pub-id-type="pmid">11873004</pub-id></mixed-citation></ref><ref id="jia225066-bib-0086"><label>86</label><mixed-citation publication-type="journal" id="jia225066-cit-0086">
<string-name>
<surname>Pi&#x000f1;a L&#x000f3;pez</surname>
<given-names>JA</given-names>
</string-name>, <string-name>
<surname>Corrales Rasc&#x000f3;n</surname>
<given-names>AE</given-names>
</string-name>, <string-name>
<surname>Mungaray Padilla</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Valencia Vidrio</surname>
<given-names>MA</given-names>
</string-name>. <article-title>Instrumento para medir variables psicol&#x000f3;gicas y comportamientos de adhesi&#x000f3;n al tratamiento en personas seropositivas frente al VIH (VPAD&#x02010;24)</article-title>. <source>Rev Panam Salud Publica</source>. <year>2006</year>;<volume>19</volume>(<issue>4</issue>):<fpage>217</fpage>&#x02013;<lpage>28</lpage>.<pub-id pub-id-type="pmid">16723062</pub-id></mixed-citation></ref><ref id="jia225066-bib-0087"><label>87</label><mixed-citation publication-type="journal" id="jia225066-cit-0087">
<string-name>
<surname>Mills</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Nachega</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Buchan</surname>
<given-names>I</given-names>
</string-name>, <string-name>
<surname>Orbinski</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Attaran</surname>
<given-names>A</given-names>
</string-name>, <string-name>
<surname>Singh</surname>
<given-names>S</given-names>
</string-name>, et&#x000a0;al. <article-title>Adherence to antiretroviral therapy in sub&#x02010;Saharan Africa and North America: a meta&#x02010;analysis</article-title>. <source>JAMA</source>. <year>2006</year>;<volume>296</volume>(<issue>6</issue>):<fpage>679</fpage>&#x02013;<lpage>90</lpage>.<pub-id pub-id-type="pmid">16896111</pub-id></mixed-citation></ref><ref id="jia225066-bib-0088"><label>88</label><mixed-citation publication-type="journal" id="jia225066-cit-0088">
<string-name>
<surname>Mhaskar</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Alandikar</surname>
<given-names>V</given-names>
</string-name>, <string-name>
<surname>Emmanuel</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Djulbegovic</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Patel</surname>
<given-names>A</given-names>
</string-name>, et&#x000a0;al. <article-title>Adherence to antiretroviral therapy in India: a systematic review and meta&#x02010;analysis</article-title>. <source>Indian J Community Med</source>. <year>2013</year>;<volume>38</volume>(<issue>2</issue>):<fpage>74</fpage>.<pub-id pub-id-type="pmid">23878418</pub-id></mixed-citation></ref><ref id="jia225066-bib-0089"><label>89</label><mixed-citation publication-type="journal" id="jia225066-cit-0089">
<string-name>
<surname>Ortego</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Huedo&#x02010;Medina</surname>
<given-names>TB</given-names>
</string-name>, <string-name>
<surname>Vejo</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Llorca</surname>
<given-names>FJ</given-names>
</string-name>. <article-title>Adherence to highly active antiretroviral therapy in Spain. A meta&#x02010;analysis</article-title>. <source>Gac Sanit</source>. <year>2011</year>;<volume>25</volume>(<issue>4</issue>):<fpage>282</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">21546132</pub-id></mixed-citation></ref><ref id="jia225066-bib-0090"><label>90</label><mixed-citation publication-type="journal" id="jia225066-cit-0090">
<string-name>
<surname>Ortego</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Huedo&#x02010;Medina</surname>
<given-names>TB</given-names>
</string-name>, <string-name>
<surname>Llorca</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Sevilla</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Santos</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Rodr&#x000ed;guez</surname>
<given-names>E</given-names>
</string-name>, et&#x000a0;al. <article-title>Adherence to highly active antiretroviral therapy (HAART): a meta&#x02010;analysis</article-title>. <source>AIDS Behav</source>. <year>2011</year>;<volume>15</volume>(<issue>7</issue>):<fpage>1381</fpage>&#x02013;<lpage>96</lpage>.<pub-id pub-id-type="pmid">21468660</pub-id></mixed-citation></ref><ref id="jia225066-bib-0091"><label>91</label><mixed-citation publication-type="journal" id="jia225066-cit-0091">
<string-name>
<surname>Malta</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Magnanini</surname>
<given-names>MMF</given-names>
</string-name>, <string-name>
<surname>Strathdee</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Bastos</surname>
<given-names>FI</given-names>
</string-name>. <article-title>Adherence to antiretroviral therapy among HIV&#x02010;infected drug users: a meta&#x02010;analysis</article-title>. <source>AIDS Behav</source>. <year>2010</year>;<volume>14</volume>(<issue>4</issue>):<fpage>731</fpage>&#x02013;<lpage>47</lpage>.<pub-id pub-id-type="pmid">19020970</pub-id></mixed-citation></ref><ref id="jia225066-bib-0092"><label>92</label><mixed-citation publication-type="journal" id="jia225066-cit-0092">
<string-name>
<surname>Nachega</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Uthman</surname>
<given-names>OA</given-names>
</string-name>, <string-name>
<surname>Anderson</surname>
<given-names>J</given-names>
</string-name>, <string-name>
<surname>Peltzer</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Wampold</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Cotton</surname>
<given-names>MF</given-names>
</string-name>, et&#x000a0;al. <article-title>Adherence to antiretroviral therapy during and after pregnancy in low&#x02010;income, middle&#x02010;income, and high&#x02010;income countries: a systematic review and meta&#x02010;analysis</article-title>. <source>AIDS</source>. <year>2012</year>;<volume>26</volume>(<issue>16</issue>):<fpage>2039</fpage>&#x02013;<lpage>52</lpage>.<pub-id pub-id-type="pmid">22951634</pub-id></mixed-citation></ref><ref id="jia225066-bib-0093"><label>93</label><mixed-citation publication-type="journal" id="jia225066-cit-0093">
<string-name>
<surname>Mountain</surname>
<given-names>E</given-names>
</string-name>, <string-name>
<surname>Mishra</surname>
<given-names>S</given-names>
</string-name>, <string-name>
<surname>Vickerman</surname>
<given-names>P</given-names>
</string-name>, <string-name>
<surname>Pickles</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Gilks</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Boily</surname>
<given-names>MC</given-names>
</string-name>. <article-title>Antiretroviral therapy uptake, attrition, adherence and outcomes among HIV&#x02010;infected female sex workers: a systematic review and meta&#x02010;analysis</article-title>. <source>PLoS ONE</source>. <year>2014</year>;<volume>9</volume>(<issue>9</issue>):<fpage>e105645</fpage>.<pub-id pub-id-type="pmid">25265158</pub-id></mixed-citation></ref><ref id="jia225066-bib-0094"><label>94</label><mixed-citation publication-type="journal" id="jia225066-cit-0094">
<string-name>
<surname>Uthman</surname>
<given-names>OA</given-names>
</string-name>, <string-name>
<surname>Oladimeji</surname>
<given-names>O</given-names>
</string-name>, <string-name>
<surname>Nduka</surname>
<given-names>C</given-names>
</string-name>. <article-title>Adherence to antiretroviral therapy among HIV&#x02010;infected prisoners: a systematic review and meta&#x02010;analysis</article-title>. <source>AIDS Care</source>. <year>2016</year>;<volume>29</volume>:<fpage>1</fpage>&#x02013;<lpage>9</lpage>.<pub-id pub-id-type="pmid">27410058</pub-id></mixed-citation></ref><ref id="jia225066-bib-0095"><label>95</label><mixed-citation publication-type="journal" id="jia225066-cit-0095">
<string-name>
<surname>Huan</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Fuzhi</surname>
<given-names>W</given-names>
</string-name>, <string-name>
<surname>Lu</surname>
<given-names>L</given-names>
</string-name>, <string-name>
<surname>Min</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Xingzhi</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Shiyang</surname>
<given-names>J</given-names>
</string-name>. <article-title>Comparisons of adherence to antiretroviral therapy in a high&#x02010; risk population in china: a systematic review and meta&#x02010;analysis</article-title>. <source>PLoS ONE</source>. <year>2016</year>;<volume>11</volume>(<issue>1</issue>):<fpage>e0146659</fpage>.<pub-id pub-id-type="pmid">26756336</pub-id></mixed-citation></ref><ref id="jia225066-bib-0096"><label>96</label><mixed-citation publication-type="journal" id="jia225066-cit-0096">
<string-name>
<surname>Martin</surname>
<given-names>D</given-names>
</string-name>, <string-name>
<surname>Luz</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Lake</surname>
<given-names>JE</given-names>
</string-name>, <string-name>
<surname>Clark</surname>
<given-names>JL</given-names>
</string-name>, <string-name>
<surname>Campos</surname>
<given-names>DP</given-names>
</string-name>, <string-name>
<surname>Veloso</surname>
<given-names>VG</given-names>
</string-name>, et&#x000a0;al. <article-title>Pharmacy refill data can be used to predict virologic failure for patients on antiretroviral therapy in Brazil</article-title>. <source>J Int AIDS Soc</source> [Internet]. <year>2017</year> Jan 1 [cited 2017 Aug 17]; <volume>20</volume>(<issue>1</issue>). Available from: <ext-link ext-link-type="uri" xlink:href="http://www.jiasociety.org/index.php/jias/article/view/21405">http://www.jiasociety.org/index.php/jias/article/view/21405</ext-link>
</mixed-citation></ref><ref id="jia225066-bib-0097"><label>97</label><mixed-citation publication-type="journal" id="jia225066-cit-0097">
<string-name>
<surname>Marmot</surname>
<given-names>M</given-names>
</string-name>. <article-title>The health gap: the challenge of an unequal world</article-title>. <source>Lancet</source>. <year>2015</year>;<volume>386</volume>(<issue>10011</issue>):<fpage>2442</fpage>&#x02013;<lpage>4</lpage>.<pub-id pub-id-type="pmid">26364261</pub-id></mixed-citation></ref><ref id="jia225066-bib-0098"><label>98</label><mixed-citation publication-type="journal" id="jia225066-cit-0098">
<string-name>
<surname>Uthman</surname>
<given-names>OA</given-names>
</string-name>, <string-name>
<surname>Magidson</surname>
<given-names>JF</given-names>
</string-name>, <string-name>
<surname>Safren</surname>
<given-names>SA</given-names>
</string-name>, <string-name>
<surname>Nachega</surname>
<given-names>JB</given-names>
</string-name>. <article-title>Depression and adherence to antiretroviral therapy in low&#x02010;, middle&#x02010; and high&#x02010;income countries: a systematic review and meta&#x02010;analysis</article-title>. <source>Curr HIV/AIDS Rep</source>. <year>2014</year>;<volume>11</volume>(<issue>3</issue>):<fpage>291</fpage>&#x02013;<lpage>307</lpage>.<pub-id pub-id-type="pmid">25038748</pub-id></mixed-citation></ref><ref id="jia225066-bib-0099"><label>99</label><mixed-citation publication-type="journal" id="jia225066-cit-0099">
<string-name>
<surname>Belaunzaran&#x02010;Zamudio</surname>
<given-names>PF</given-names>
</string-name>, <string-name>
<surname>Caro&#x02010;Vega</surname>
<given-names>YN</given-names>
</string-name>, <string-name>
<surname>Shepherd</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Crabtree&#x02010;Ramirez</surname>
<given-names>BE</given-names>
</string-name>, <string-name>
<surname>Luz</surname>
<given-names>PM</given-names>
</string-name>, <string-name>
<surname>Grinsztejn</surname>
<given-names>B</given-names>
</string-name>, et&#x000a0;al. <article-title>Monitoring of HIV treatment in seven countries in the WHO Region of the Americas</article-title>. <source>Bull World Health Organ</source>. <year>2015</year>;<volume>93</volume>(<issue>8</issue>):<fpage>529</fpage>&#x02013;<lpage>39</lpage>.<pub-id pub-id-type="pmid">26478610</pub-id></mixed-citation></ref><ref id="jia225066-bib-0100"><label>100</label><mixed-citation publication-type="journal" id="jia225066-cit-0100">
<string-name>
<surname>Paterson</surname>
<given-names>DL</given-names>
</string-name>, <string-name>
<surname>Potoski</surname>
<given-names>B</given-names>
</string-name>, <string-name>
<surname>Capitano</surname>
<given-names>B</given-names>
</string-name>. <article-title>Measurement of adherence to antiretroviral medications</article-title>. <source>J Acquir Immune Defic Syndr</source>. <year>1999</year>;<volume>2002</volume>(<issue>31 Suppl 3</issue>):<fpage>S103</fpage>&#x02013;<lpage>6</lpage>.</mixed-citation></ref><ref id="jia225066-bib-0101"><label>101</label><mixed-citation publication-type="journal" id="jia225066-cit-0101">
<string-name>
<surname>Turner</surname>
<given-names>BJ</given-names>
</string-name>. <article-title>Adherence to antiretroviral therapy by human immunodeficiency virus&#x02010;infected patients</article-title>. <source>J Infect Dis</source>. <year>2002</year>;<volume>185</volume>(<issue>Suppl 2</issue>):<fpage>S143</fpage>&#x02013;<lpage>51</lpage>.<pub-id pub-id-type="pmid">12001036</pub-id></mixed-citation></ref><ref id="jia225066-bib-0102"><label>102</label><mixed-citation publication-type="journal" id="jia225066-cit-0102">
<string-name>
<surname>Williams</surname>
<given-names>AB</given-names>
</string-name>, <string-name>
<surname>Amico</surname>
<given-names>KR</given-names>
</string-name>, <string-name>
<surname>Bova</surname>
<given-names>C</given-names>
</string-name>, <string-name>
<surname>Womack</surname>
<given-names>JA</given-names>
</string-name>. <article-title>A proposal for quality standards for measuring medication adherence in research</article-title>. <source>AIDS Behav</source>. <year>2013</year>;<volume>17</volume>(<issue>1</issue>):<fpage>284</fpage>&#x02013;<lpage>97</lpage>.<pub-id pub-id-type="pmid">22407465</pub-id></mixed-citation></ref><ref id="jia225066-bib-0103"><label>103</label><mixed-citation publication-type="journal" id="jia225066-cit-0103">
<string-name>
<surname>Latkin</surname>
<given-names>CA</given-names>
</string-name>, <string-name>
<surname>Knowlton</surname>
<given-names>AR</given-names>
</string-name>. <article-title>Social network assessments and interventions for health behavior change: a critical review</article-title>. <source>Behav Med</source>. <year>2015</year>;<volume>41</volume>(<issue>3</issue>):<fpage>90</fpage>&#x02013;<lpage>7</lpage>.<pub-id pub-id-type="pmid">26332926</pub-id></mixed-citation></ref><ref id="jia225066-bib-0104"><label>104</label><mixed-citation publication-type="journal" id="jia225066-cit-0104">
<string-name>
<surname>Petry</surname>
<given-names>NM</given-names>
</string-name>. <article-title>Alcohol use in HIV patients: what we don't know may hurt us</article-title>. <source>Int J STD AIDS</source>. <year>1999</year>;<volume>10</volume>(<issue>9</issue>):<fpage>561</fpage>&#x02013;<lpage>70</lpage>.<pub-id pub-id-type="pmid">10492422</pub-id></mixed-citation></ref><ref id="jia225066-bib-0105"><label>105</label><mixed-citation publication-type="journal" id="jia225066-cit-0105">
<string-name>
<surname>Nachega</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Uthman</surname>
<given-names>OA</given-names>
</string-name>, <string-name>
<surname>Peltzer</surname>
<given-names>K</given-names>
</string-name>, <string-name>
<surname>Richardson</surname>
<given-names>LA</given-names>
</string-name>, <string-name>
<surname>Mills</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Amekudzi</surname>
<given-names>K</given-names>
</string-name>, et&#x000a0;al. <article-title>Association between antiretroviral therapy adherence and employment status: systematic review and meta&#x02010;analysis</article-title>. <source>Bull World Health Organ</source>. <year>2015</year>;<volume>93</volume>(<issue>1</issue>):<fpage>29</fpage>&#x02013;<lpage>41</lpage>.<pub-id pub-id-type="pmid">25558105</pub-id></mixed-citation></ref><ref id="jia225066-bib-0106"><label>106</label><mixed-citation publication-type="journal" id="jia225066-cit-0106">
<string-name>
<surname>Shubber</surname>
<given-names>Z</given-names>
</string-name>, <string-name>
<surname>Mills</surname>
<given-names>EJ</given-names>
</string-name>, <string-name>
<surname>Nachega</surname>
<given-names>JB</given-names>
</string-name>, <string-name>
<surname>Vreeman</surname>
<given-names>R</given-names>
</string-name>, <string-name>
<surname>Freitas</surname>
<given-names>M</given-names>
</string-name>, <string-name>
<surname>Bock</surname>
<given-names>P</given-names>
</string-name>, et&#x000a0;al. <article-title>Patient&#x02010;reported barriers to adherence to antiretroviral therapy: a systematic review and meta&#x02010;analysis</article-title>. Weiser SD, editor. <source>PLoS Med</source>. <year>2016</year>;<volume>13</volume>(<issue>11</issue>):<fpage>e1002183</fpage>.<pub-id pub-id-type="pmid">27898679</pub-id></mixed-citation></ref><ref id="jia225066-bib-0107"><label>107</label><mixed-citation publication-type="book" id="jia225066-cit-0107">
<collab collab-type="authors">Organiza&#x000e7;&#x000e3;o Pan&#x02010;americana de Sa&#x000fa;de</collab>
. <source>Antiretroviral treatment in the spotlight: a public health analysis in Latin America and the Caribbean</source>. <publisher-loc>Washington&#x02010;DC</publisher-loc>: <publisher-name>OPAS/PAHO</publisher-name>; <year>2013</year>.</mixed-citation></ref><ref id="jia225066-bib-0108"><label>108</label><mixed-citation publication-type="book" id="jia225066-cit-0108">
<collab collab-type="authors">Organiza&#x000e7;&#x000e3;o Pan&#x02010;americana de Sa&#x000fa;de</collab>
. <source>Antiretroviral treatment in the spotlight: a public health analysis in Latin America and the Caribbean 2014. Key Messages</source>. <publisher-loc>Washington&#x02010;DC</publisher-loc>: <publisher-name>OPAS/PAHO</publisher-name>; <year>2014</year>.</mixed-citation></ref><ref id="jia225066-bib-0109"><label>109</label><mixed-citation publication-type="journal" id="jia225066-cit-0109">
<string-name>
<surname>Ioannidis</surname>
<given-names>JPA</given-names>
</string-name>, <string-name>
<surname>Patsopoulos</surname>
<given-names>NA</given-names>
</string-name>, <string-name>
<surname>Rothstein</surname>
<given-names>HR</given-names>
</string-name>. <article-title>Reasons or excuses for avoiding meta&#x02010;analysis in forest plots</article-title>. <source>BMJ</source>. <year>2008</year>;<volume>336</volume>(<issue>7658</issue>):<fpage>1413</fpage>&#x02013;<lpage>5</lpage>.<pub-id pub-id-type="pmid">18566080</pub-id></mixed-citation></ref></ref-list></back></article>